<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK153722" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK153722/" /><meta name="ncbi_pagename" content="PIK3CA-Related Segmental Overgrowth - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>PIK3CA-Related Segmental Overgrowth - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="PIK3CA-Related Segmental Overgrowth" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/08/15" /><meta name="citation_author" content="Ghayda Mirzaa" /><meta name="citation_author" content="Robert Conway" /><meta name="citation_author" content="John M Graham, Jr" /><meta name="citation_author" content="William B Dobyns" /><meta name="citation_pmid" content="23946963" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK153722/" /><meta name="citation_keywords" content="Megalencephaly-Capillary Malformation Syndrome (MCAP Syndrome)" /><meta name="citation_keywords" content="CLOVES Syndrome" /><meta name="citation_keywords" content="Fibroadipose Hyperplasia" /><meta name="citation_keywords" content="Hemimegalencephaly" /><meta name="citation_keywords" content="Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform" /><meta name="citation_keywords" content="PIK3CA" /><meta name="citation_keywords" content="PIK3CA-Related Segmental Overgrowth" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="PIK3CA-Related Segmental Overgrowth" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Ghayda Mirzaa" /><meta name="DC.Contributor" content="Robert Conway" /><meta name="DC.Contributor" content="John M Graham, Jr" /><meta name="DC.Contributor" content="William B Dobyns" /><meta name="DC.Date" content="2013/08/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK153722/" /><meta name="description" content="PIK3CA-associated segmental overgrowth includes disorders of brain (e.g., MCAP [megalencephaly-capillary malformation] syndrome, hemimegalencephaly); and segmental body overgrowth (e.g., CLOVES [congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies] syndrome, fibroadipose hyperplasia [FH]). Heterozygous (usually somatic mosaic) pathogenic variants of PIK3CA are causative." /><meta name="og:title" content="PIK3CA-Related Segmental Overgrowth" /><meta name="og:type" content="book" /><meta name="og:description" content="PIK3CA-associated segmental overgrowth includes disorders of brain (e.g., MCAP [megalencephaly-capillary malformation] syndrome, hemimegalencephaly); and segmental body overgrowth (e.g., CLOVES [congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies] syndrome, fibroadipose hyperplasia [FH]). Heterozygous (usually somatic mosaic) pathogenic variants of PIK3CA are causative." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK153722/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/pik3ca-overgrowth/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK153722/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CCD59E04012810000000006C40262.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK153722_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK153722_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aniridia/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pink1-pd/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK153722_"><span class="title" itemprop="name"><i>PIK3CA</i>-Related Segmental Overgrowth</span></h1><p class="contrib-group"><span itemprop="author">Ghayda Mirzaa</span>, MD, FAAP, FACMG, <span itemprop="author">Robert Conway</span>, MD, <span itemprop="author">John M Graham, Jr</span>, MD, ScD, and <span itemprop="author">William B Dobyns</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK153722_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK153722_ai__"><div class="contrib half_rhythm"><span itemprop="author">Ghayda Mirzaa</span>, MD, FAAP, FACMG<div class="affiliation small">Seattle Children's Research Institute<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wu@aazrimg" class="oemail">ude.wu@aazrimg</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Robert Conway</span>, MD<div class="affiliation small">Wayne State University<br />Detroit, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.enyaw.dem@yawnocr" class="oemail">ude.enyaw.dem@yawnocr</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John M Graham, Jr</span>, MD, ScD<div class="affiliation small">Cedars Sinai Medical Center<br />Los Angeles, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.shsc@maharg.nhoj" class="oemail">gro.shsc@maharg.nhoj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">William B Dobyns</span>, MD<div class="affiliation small">Seattle Children's Hospital<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wu@dbw" class="oemail">ude.wu@dbw</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 15, 2013</span>.</p><p><em>Estimated reading time: 38 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="pik3ca-overgrowth.Summary" itemprop="description"><h2 id="_pik3ca-overgrowth_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>PIK3CA</i>-associated segmental overgrowth includes disorders of brain (e.g., MCAP [<i>m</i>egalencephaly-<i>cap</i>illary malformation] syndrome, hemimegalencephaly); and segmental body overgrowth (e.g., CLOVES [<i>c</i>ongenital <i>l</i>ipomatous asymmetric <i>o</i>vergrowth of the trunk, lymphatic, capillary, venous, and combined-type <i>v</i>ascular malformations, <i>e</i>pidermal nevi, <i>s</i>keletal and <i>s</i>pinal anomalies] syndrome, fibroadipose hyperplasia [FH]). Heterozygous (usually somatic mosaic) pathogenic variants of <i>PIK3CA</i> are causative.</p><p>MCAP syndrome is characterized by the major findings of (1) megalencephaly (MEG) or hemimegalencephaly (HMEG) associated with neurologic findings of hypotonia, seizures, and mild to severe intellectual disability; and (2) cutaneous capillary malformations with focal or generalized somatic overgrowth. Additional findings can include digital anomalies (syndactyly, polydactyly), cortical malformations &#x02013; most distinctively polymicrogyria (PMG); and variable connective tissue dysplasia.</p><p>CLOVES (or CLOVE) syndrome and fibroadipose hyperplasia (FH) may be associated with (1) MEG or HMEG; and (2) patchy segmental overgrowth associated with skeletal anomalies, lipomatosis, vascular malformations, and epidermal nevi.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p><i>PIK3CA</i>-associated segmental overgrowth is confirmed in an individual with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on one <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, typically in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues. Because the vast majority of <i>PIK3CA</i> pathogenic variants arise postzygotic (and are thus mosaic), more than one tissue may need to be tested. Failure to detect a <i>PIK3CA</i> pathogenic variant does not exclude a clinical diagnosis of the <i>PIK3CA</i>-associated segmental overgrowth disorders in individuals with suggestive features.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Significant or lipomatous segmental overgrowth may require debulking; scoliosis and leg-length discrepancy may require orthopedic care and surgical intervention. Neurologic complications (e.g., obstructive hydrocephalus, increased intracranial pressure, progressive and/or symptomatic cerebellar tonsillar ectopia or Chiari malformation; epilepsy in those with HMEG) may warrant neurosurgical intervention. Routine treatment of the following, when present, is indicated: cardiac and renal abnormalities; intellectual disabilities and behavior problems; motor difficulties; speech, swallowing, and feeding difficulties.</p><p><i>Surveillance:</i></p><ul><li class="half_rhythm"><div>MCAP syndrome: Follow up no less than every six months until age six years and at least yearly thereafter to monitor for neurosurgical complications, breathing or sleep disorders, seizures and orthopedic complications. Provisionally recommended imaging in early childhood includes brain MRI every six months for the first two years, then yearly until age eight years for neurologic complications (e.g., hydrocephalus, cerebellar tonsillar ectopia). Consider screening for Wilms tumor following the protocol suggested for Beckwith-Wiedemann syndrome (BWS) (by ultrasound examination every 3 months until age 8 years); however, tumor risk in <i>PIK3CA</i>-related segmental overgrowth is undetermined and appears to be lower than in BWS.</div></li><li class="half_rhythm"><div>CLOVES syndrome and FH: Monitoring for severe scoliosis, infiltrative lipomatous overgrowth, paraspinal high-flow lesions with spinal cord ischemia, lymphatic malformations, cutaneous vesicles, orthopedic problems, central phlebectasias, and thromboembolism.</div></li></ul></div><div><h4 class="inline">Genetic counseling.</h4><p><i>PIK3CA</i>-associated segmental overgrowth is not typically inherited. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with MCAP reported to date (21/24) had <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for pathogenic variants in <i>PIK3CA,</i> suggesting that mutation occurred post-fertilization in one cell of the multicellular embryo. Two of 24 affected individuals had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PIK3CA.</i> All reported individuals with CLOVES and FH had somatic mosaicism for pathogenic variants in <i>PIK3CA</i>. No confirmed instances of vertical transmission or sib recurrence have been reported. Because family members are not known to have an increased risk, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> is usually not indicated for family members.</p></div></div><div id="pik3ca-overgrowth.GeneReview_Scope"><h2 id="_pik3ca-overgrowth_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="pik3ca-overgrowth.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pik3ca-overgrowth.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>PIK3CA</i>-Related Segmental Overgrowth: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_pik3ca-overgrowth.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>CLOVES syndrome</div></li><li class="half_rhythm"><div>Megalencephaly-capillary malformation syndrome (MCAP syndrome)</div></li><li class="half_rhythm"><div>Fibroadipose hyperplasia</div></li><li class="half_rhythm"><div>Hemimegalencephaly</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#pik3ca-overgrowth.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="pik3ca-overgrowth.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#pik3ca-overgrowth.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="pik3ca-overgrowth.Diagnosis"><h2 id="_pik3ca-overgrowth_Diagnosis_">Diagnosis</h2><p><i>PIK3CA</i>-associated segmental overgrowth includes brain (e.g., megalencephaly-capillary [MCAP] malformation syndrome, hemimegalencephaly) and segmental body overgrowth (e.g., CLOVES syndrome, fibroadipose hyperplasia [FH]) caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (usually somatic mosaic) <i>PIK3CA</i> pathogenic variants.</p><div id="pik3ca-overgrowth.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>PIK3CA</i>-associated segmental overgrowth <b>is suspected</b> in an individual with clinical features of the following syndromes. Of note, some individuals with low-level <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for <i>PIK3CA</i> somatic pathogenic variants may have phenotypes that do not meet clinical diagnostic criteria.</p><p><b>Megalencephaly-capillary malformation (MCAP) syndrome</b> (<a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.findings_in_mcap_syn/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTfindingsinmcapsyn" rid-ob="figobpik3caovergrowthTfindingsinmcapsyn">Table 1</a>) (<a class="figpopup" href="/books/NBK153722/figure/pik3ca-overgrowth.F1/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthF1" rid-ob="figobpik3caovergrowthF1">Figure 1</a> and <a class="figpopup" href="/books/NBK153722/figure/pik3ca-overgrowth.F2/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthF2" rid-ob="figobpik3caovergrowthF2">Figure 2</a>) is characterized by the major findings (1) megalencephaly (MEG) (<a class="figpopup" href="/books/NBK153722/figure/pik3ca-overgrowth.F3/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthF3" rid-ob="figobpik3caovergrowthF3">Figure 3</a>) or hemimegalencephaly (HMEG) associated with abnormalities of muscle tone, seizures, and mild to severe intellectual disability, and (2) cutaneous capillary malformations with focal or generalized somatic overgrowth. Additional findings can include digital anomalies consisting of syndactyly and polydactyly; cortical malformations, most distinctively polymicrogyria (PMG) (<a class="figpopup" href="/books/NBK153722/figure/pik3ca-overgrowth.F3/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthF3" rid-ob="figobpik3caovergrowthF3">Figure 3</a>); and variable connective tissue dysplasia [<a class="bk_pop" href="#pik3ca-overgrowth.REF.franceschini.2000.265">Franceschini et al 2000</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.robertson.2000.1">Robertson et al 2000</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.giuliano.2004.99">Giuliano et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lapunzina.2004.45">Lapunzina et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al 2009</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mart_nezglez.2010.3101">Mart&#x000ed;nez-Glez et al 2010</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figpik3caovergrowthF1" co-legend-rid="figlgndpik3caovergrowthF1"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figpik3caovergrowthF1" rid-ob="figobpik3caovergrowthF1"><img class="small-thumb" src="/books/NBK153722/bin/pik3ca-overgrowth-Image001.gif" src-large="/books/NBK153722/bin/pik3ca-overgrowth-Image001.jpg" alt="Figure 1. . Features of MCAP syndrome." /></a><div class="icnblk_cntnt" id="figlgndpik3caovergrowthF1"><h4 id="pik3ca-overgrowth.F1"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F1/?report=objectonly" target="object" rid-ob="figobpik3caovergrowthF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Features of MCAP syndrome. Photographs of an individual with MCAP syndrome demonstrating the apparent macrocephaly with prominent forehead (D); extensive capillary malformations (A-F1); bilateral 2-3-4 toe syndactyly (G,H); 3-4 finger syndactyly (F1,F2); <a href="/books/NBK153722/figure/pik3ca-overgrowth.F1/?report=objectonly" target="object" rid-ob="figobpik3caovergrowthF1">(more...)</a></p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figpik3caovergrowthF2" co-legend-rid="figlgndpik3caovergrowthF2"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figpik3caovergrowthF2" rid-ob="figobpik3caovergrowthF2"><img class="small-thumb" src="/books/NBK153722/bin/pik3ca-overgrowth-Image002.gif" src-large="/books/NBK153722/bin/pik3ca-overgrowth-Image002.jpg" alt="Figure 2. . Features of MCAP syndrome." /></a><div class="icnblk_cntnt" id="figlgndpik3caovergrowthF2"><h4 id="pik3ca-overgrowth.F2"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F2/?report=objectonly" target="object" rid-ob="figobpik3caovergrowthF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Features of MCAP syndrome. A boy age 40 months with MCAP syndrome (left) and his unaffected twin sister (right). Note left-sided hemihypertrophy, typical facial features, bilateral 2-3 toe syndactyly, and connective tissue dysplasia with loose redundant <a href="/books/NBK153722/figure/pik3ca-overgrowth.F2/?report=objectonly" target="object" rid-ob="figobpik3caovergrowthF2">(more...)</a></p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figpik3caovergrowthF3" co-legend-rid="figlgndpik3caovergrowthF3"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figpik3caovergrowthF3" rid-ob="figobpik3caovergrowthF3"><img class="small-thumb" src="/books/NBK153722/bin/pik3ca-overgrowth-Image003.gif" src-large="/books/NBK153722/bin/pik3ca-overgrowth-Image003.jpg" alt="Figure 3. . Characteristic brain MRI of MCAP syndrome in three individuals (A-D, E-H, and I-L)." /></a><div class="icnblk_cntnt" id="figlgndpik3caovergrowthF3"><h4 id="pik3ca-overgrowth.F3"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F3/?report=objectonly" target="object" rid-ob="figobpik3caovergrowthF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Characteristic brain MRI of MCAP syndrome in three individuals (A-D, E-H, and I-L). Note: Megalencephaly with a prominent forehead (A, E, I); cerebellar tonsillar ectopia with a large cerebellum and crowded posterior fossa (A, E, I); ventriculomegaly <a href="/books/NBK153722/figure/pik3ca-overgrowth.F3/?report=objectonly" target="object" rid-ob="figobpik3caovergrowthF3">(more...)</a></p></div></div><p>Hemimegalencephaly (HMEG) is characterized by partial or complete enlargement and dysplasia of a cerebral hemisphere, often with variable contralateral involvement. Complex abnormalities (typically noted on brain imaging) include cortical dysgenesis, abnormally increased white matter, and dilated and <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> lateral ventricles [<a class="bk_pop" href="#pik3ca-overgrowth.REF.barkovich.1990.523">Barkovich &#x00026; Chuang 1990</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.floressarnat.2002.373">Flores-Sarnat 2002</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.floressarnat.2003.776">Flores-Sarnat et al 2003</a>].</p><div id="pik3ca-overgrowth.T.findings_in_mcap_syn" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Findings in MCAP Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.T.findings_in_mcap_syn/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.T.findings_in_mcap_syn_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1" colspan="4" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Finding</th></tr><tr><th headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1" id="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1" id="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Major</th><th headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1" id="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Supportive</th><th headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1" id="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Secondary</th></tr></thead><tbody><tr><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Early segmental</b><br /><b>overgrowth</b><br /><b>(brain &#x0003e; somatic</b><br /><b>tissues)</b></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive MEG or HMEG&#x000a0;<sup>1</sup></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ventriculomegaly or hydrocephalus</div></li><li class="half_rhythm"><div>Cerebellar tonsillar ectopia or Chiari malformation</div></li><li class="half_rhythm"><div>Abnormally thick (mega-) corpus callosum</div></li><li class="half_rhythm"><div>Congenital somatic overgrowth (generalized/focal)</div></li><li class="half_rhythm"><div>Somatic or cranial asymmetry</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>DD</div></li><li class="half_rhythm"><div>Distinctive facial features: frontal bossing &#x00026; dolichocephaly</div></li></ul>
</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Developmental</b><br /><b>vascular</b><br /><b>disorders</b><br /><b>(abnormal</b><br /><b>vasculogenesis)</b></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cutaneous capillary malformations:&#x000a0;<sup>1</sup>
<ul><li class="half_rhythm"><div>Midline face (esp. persistent nevus flammeus)</div></li><li class="half_rhythm"><div>Body: widespread (or rarely vivid cutis marmorata)</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Venous aneurysms / prominent venous pattern</div></li><li class="half_rhythm"><div>Aberrant vasculature / vascular rings</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Digital anomalies</b></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Syndactyly (2-3, 3-4, 2-3-4):
<ul><li class="half_rhythm"><div>Toes: 2-3 &#x0003e; others</div></li><li class="half_rhythm"><div>Fingers: 3-4 &#x0003e; others</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Postaxial polydactyly</div></li><li class="half_rhythm"><div>Polysyndactyly</div></li><li class="half_rhythm"><div>Sandal-gap toes</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cortical brain</b><br /><b>malformations</b></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PMG</td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>DD</div></li></ul>
</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Connective tissue</b><br /><b>dysplasia</b></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Skin hyperelasticity</div></li><li class="half_rhythm"><div>Joint hypermobility</div></li><li class="half_rhythm"><div>Thick, soft, (or "doughy") subcutaneous tissue</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_1_1 hd_h_pik3ca-overgrowth.T.findings_in_mcap_syn_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Gross DD</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">DD = developmental delay; HMEG = hemimegalencephaly; MEG = megalencephaly; PMG = polymicrogyria</p></div></dd><dt></dt><dd><div><p class="no_margin">Based on <a class="bk_pop" href="#pik3ca-overgrowth.REF.franceschini.2000.265">Franceschini et al [2000]</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.robertson.2000.1">Robertson et al [2000]</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.giuliano.2004.99">Giuliano et al [2004]</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lapunzina.2004.45">Lapunzina et al [2004]</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al [2009]</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mart_nezglez.2010.3101">Mart&#x000ed;nez-Glez et al [2010]</a></p></div></dd><dt>1. </dt><dd><div id="pik3ca-overgrowth.TF.1.1"><p class="no_margin">MCAP syndrome can be diagnosed based on clinical findings in individuals with classic features of MEG or HMEG (major finding 1) and characteristic capillary malformations (major finding 2).</p></div></dd></dl></div></div></div><p><b>CLOVES (or CLOVE) syndrome and fibroadipose hyperplasia</b> (<a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.classic_features_of/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTclassicfeaturesof" rid-ob="figobpik3caovergrowthTclassicfeaturesof">Table 2</a>) may be associated with MEG or HMEG, and thus overlap with MCAP syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.gucev.2008.2688">Gucev et al 2008</a>]. Findings include patchy segmental overgrowth associated with skeletal anomalies, lipomatosis, vascular malformations, and epidermal nevi. Given the clinical and molecular genetic overlap between CLOVES syndrome and fibroadipose hyperplasia, these two conditions may constitute a single large spectrum of somatic overgrowth.</p><p>CLOVES syndrome is characterized by <i>c</i>ongenital <i>l</i>ipomatous asymmetric <i>o</i>vergrowth of the trunk, lymphatic, capillary, venous, and combined-type <i>v</i>ascular malformations, <i>e</i>pidermal nevi, <i>s</i>keletal and <i>s</i>pinal anomalies. CLOVES syndrome differs from MCAP syndrome by more striking growth dysregulation with complex <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> overgrowth of lipomatous tissues (typically manifest as a truncal lipomatous mass) and combined lymphatic and vascular malformations (<a class="figpopup" href="/books/NBK153722/figure/pik3ca-overgrowth.F4/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthF4" rid-ob="figobpik3caovergrowthF4">Figure 4A</a>). Skeletal anomalies include scoliosis, wide hands and feet, macrodactyly (<a class="figpopup" href="/books/NBK153722/figure/pik3ca-overgrowth.F4/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthF4" rid-ob="figobpik3caovergrowthF4">Figure 4B</a>), and prominent sandal-gap toes [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figpik3caovergrowthF4" co-legend-rid="figlgndpik3caovergrowthF4"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F4/?report=objectonly" target="object" title="Figure 4. " class="img_link icnblk_img figpopup" rid-figpopup="figpik3caovergrowthF4" rid-ob="figobpik3caovergrowthF4"><img class="small-thumb" src="/books/NBK153722/bin/pik3ca-overgrowth-Image004.gif" src-large="/books/NBK153722/bin/pik3ca-overgrowth-Image004.jpg" alt="Figure 4. " /></a><div class="icnblk_cntnt" id="figlgndpik3caovergrowthF4"><h4 id="pik3ca-overgrowth.F4"><a href="/books/NBK153722/figure/pik3ca-overgrowth.F4/?report=objectonly" target="object" rid-ob="figobpik3caovergrowthF4">Figure 4. </a></h4><p class="float-caption no_bottom_margin">Features of CLOVES syndrome in a child with (A) a large lipomatous truncal mass that extends into the surrounding tissues and an overlying capillary malformation and (B) macrodactyly of the left foot </p></div></div><p>Fibroadipose hyperplasia, a severe overgrowth syndrome recently described in ten individuals with mosaic <i>PIK3CA</i> pathogenic variants [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>], is characterized by progressive segmental overgrowth of visceral, subcutaneous, muscular, fibroadipose, and skeletal tissues, and may involve the trunk or extremities. Other variable features include lipomatous infiltration of muscle, progressive adipose dysregulation and regional lipohypoplasia, vascular malformations, testicular abnormalities, and polydactyly.</p><div id="pik3ca-overgrowth.T.classic_features_of" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Classic Features of CLOVES Syndrome and Fibroadipose Hyperplasia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.T.classic_features_of/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.T.classic_features_of_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feature</th><th id="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CLOVES Syndrome</th><th id="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fibroadipose Hyperplasia&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Overgrowth</b></td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Lipomatous overgrowth (typically truncal, complex, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>, progressive)</div></li><li class="half_rhythm"><div>Spinal-paraspinal extension</div></li><li class="half_rhythm"><div>Limb &#x00026; digital overgrowth</div></li><li class="half_rhythm"><div>Bony overgrowth, leg-length discrepancy</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Visceral, subcutaneous, muscular fibroadipose, &#x00026; skeletal tissues (<a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>, progressive; may involve trunk or extremities)</div></li><li class="half_rhythm"><div>Lipomatous infiltration of muscle (in 6/10)</div></li><li class="half_rhythm"><div>Disproportionate linear overgrowth (in 10/10)</div></li></ul>
</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cutaneous &#x00026;</b><br /><b>vascular</b><br /><b>malformations</b></td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Low-flow (capillary, venous, lymphatic; typically overlying truncal overgrowth)</div></li><li class="half_rhythm"><div>High-flow (arteriovenous; esp. spinal-paraspinal)</div></li><li class="half_rhythm"><div>Venous thrombosis/embolism</div></li><li class="half_rhythm"><div>Epidermal nevi (single/multiple)</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Vascular malformation (in 2/10)</div></li><li class="half_rhythm"><div>Epidermal nevi (in 2/10)</div></li></ul>
</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal/</b><br /><b>acral</b><br /><b>abnormalities</b></td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Scoliosis</div></li><li class="half_rhythm"><div>Chondromalacia patellae</div></li><li class="half_rhythm"><div>Dislocated knees</div></li><li class="half_rhythm"><div>Macrodactyly, wide hands/feet</div></li><li class="half_rhythm"><div>Sandal gap toes</div></li><li class="half_rhythm"><div>Symmetric overgrowth of feet</div></li><li class="half_rhythm"><div>Plantar-palmar overgrowth</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive skeletal overgrowth (preserved architecture)</div></li><li class="half_rhythm"><div>Polydactyly</div></li></ul>
</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Visceral</b><br /><b>abnormalities</b></td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Renal agenesis/hypoplasia</div></li><li class="half_rhythm"><div>Splenic lesions</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Testicular or epididymal cysts &#x00026; hydrocele (in 3/10)</div></li><li class="half_rhythm"><div>Non-spleen / thymus visceral overgrowth (in 1/10)</div></li></ul>
</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b><br /><b>abnormalities</b></td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Neural tube defect</div></li><li class="half_rhythm"><div>Tethered cord</div></li><li class="half_rhythm"><div>Megalencephaly / hemimegalencephaly</div></li><li class="half_rhythm"><div>Chiari malformation</div></li><li class="half_rhythm"><div>Polymicrogyria</div></li></ul>
</td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_pik3ca-overgrowth.T.classic_features_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Regional lipohypoplasia</div></li><li class="half_rhythm"><div>Progressive adipose dysregulation</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="pik3ca-overgrowth.TF.2.1"><p class="no_margin">Features variably identified in ten <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</p></div></dd></dl></div></div></div></div><div id="pik3ca-overgrowth.Establishing_the_Diagn"><h3>Establishing the Diagnosis</h3><p><i>PIK3CA</i>-associated segmental overgrowth <b>is confirmed</b> in an individual with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on one <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> who meets clinical criteria. In an individual with ambiguous or mild clinical findings [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>] (<a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.molecular_genetic_te/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTmoleculargeneticte" rid-ob="figobpik3caovergrowthTmoleculargeneticte">Table 3</a>), identification of a <i>PIK3CA</i> pathogenic variant <b>establishes</b> the diagnosis of <i>PIK3CA</i>-associated segmental overgrowth.</p><p>Because the vast majority of reported <i>PIK3CA</i> pathogenic variants are postzygotic (and thus mosaic), more than one tissue may need to be tested.</p><ul><li class="half_rhythm"><div>Experience suggests that <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of DNA derived from saliva or skin (whether visibly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or not) has a higher detection rate than of peripheral blood-derived DNA.</div></li><li class="half_rhythm"><div>In highly focal disorders such as HMEG, CLOVES, and fibroadipose hyperplasia, pathogenic variants are only detectable in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues. Therefore, absence of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a DNA sample is insufficient to exclude the diagnosis [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lee.2012.941">Lee et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>].</div></li><li class="half_rhythm"><div>Failure to detect a <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> does not exclude a clinical diagnosis of <i>PIK3CA</i>-associated segmental overgrowth disorders in individuals with suggestive features, given that low-level <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> is observed in many individuals. Furthermore, <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity is a possibility (see <a href="#pik3ca-overgrowth.Differential_Diagnosis">Differential Diagnosis</a>).</div></li><li class="half_rhythm"><div>Sensitivity to detect low-level <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> of a <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is theoretically greatest using massively parallel sequencing (also known as <a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a>) in tissues other than blood, and in particular will be of high yield when analyzing <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues in disorders other than MCAP syndrome.</div></li></ul><div id="pik3ca-overgrowth.T.molecular_genetic_te" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>PIK3CA</i>-associated Segmental Overgrowth</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.T.molecular_genetic_te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.T.molecular_genetic_te_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic Variant Detection Frequency by Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PIK3CA</i></td><td headers="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants&#x000a0;<sup>5</sup></td><td headers="hd_h_pik3ca-overgrowth.T.molecular_genetic_te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dependent on <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, tissue analyzed, and method&#x000a0;<sup>6,&#x000a0;7,&#x000a0;8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="pik3ca-overgrowth.TF.3.1"><p class="no_margin">See <a href="/books/NBK153722/#pik3ca-overgrowth.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="pik3ca-overgrowth.TF.3.2"><p class="no_margin">See <a href="#pik3ca-overgrowth.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="pik3ca-overgrowth.TF.3.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="pik3ca-overgrowth.TF.3.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="pik3ca-overgrowth.TF.3.5"><p class="no_margin">Most identified <i>PIK3CA</i> pathogenic variants to date are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, with only a single <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> 3-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> identified in MCAP syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>]. No <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, large deletions, or duplications involving <i>PIK3CA</i> have been identified to date.</p></div></dd><dt>6. </dt><dd><div id="pik3ca-overgrowth.TF.3.6"><p class="no_margin">For MCAP syndrome: 21/24 individuals had <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for a <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; 2/24 had a <i>de novo PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a>; and 1/24 had inconclusive results with only one sample available for testing [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>]. The level of mosaicism varied by the tissue being tested and ranged from 1% to 48%. In individuals in whom three or more tissues were analyzed, blood was the tissue in which the lowest level of mosaicism was observed [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>]. The level of mosaicism was below 25% in 15 of 18 (83%) samples of blood-derived DNA and in 11 of 22 (45%) samples of saliva- or skin-derived DNA. Detection of these pathogenic variants was facilitated by massively parallel sequencing and would likely have been missed by standard Sanger <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p></div></dd><dt>7. </dt><dd><div id="pik3ca-overgrowth.TF.3.7"><p class="no_margin">For CLOVES, FH, HMEG: Pathogenic variants were identified in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues (including brain in hemimegalencephaly) with mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> frequencies ranging from 1% to 49% overall. The pathogenic variants were not identified in DNA derived from blood (or, in some studies, from either blood or saliva) [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lee.2012.941">Lee et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>].</p></div></dd><dt>8. </dt><dd><div id="pik3ca-overgrowth.TF.3.8"><p class="no_margin">For HMEG: The same <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (<a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">c.1633G&#x0003e;A</a>) was identified in four brain samples of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div></dd></dl></div></div></div></div></div><div id="pik3ca-overgrowth.Clinical_Characteristi"><h2 id="_pik3ca-overgrowth_Clinical_Characteristi_">Clinical Characteristics</h2><div id="pik3ca-overgrowth.Clinical_Description"><h3>Clinical Description</h3><p><i>PIK3CA</i>-associated segmental overgrowth includes disorders of brain overgrowth (the megalencephaly-capillary (MCAP) malformation syndrome and hemimegalencephaly) and lipomatous body overgrowth (CLOVES syndrome, and fibroadipose hyperplasia [FH]) caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (usually somatic mosaic) <i>PIK3CA</i> pathogenic variants.</p><div id="pik3ca-overgrowth.MegalencephalyCapillar"><h4>Megalencephaly-Capillary Malformation (MCAP) Syndrome</h4><p>The MCAP syndrome involves striking growth dysregulation manifesting as overgrowth of the brain and multiple somatic tissues. The features vary widely in number and severity among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>Those with classic features have <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> or early postnatal megalencephaly (MEG; occipitofrontal circumference [OFC] &#x02265;3 SD above the mean); segmental or generalized somatic overgrowth; single or generalized capillary malformations (most commonly a midline facial capillary malformation, or cutis marmorata); and generalized hypotonia.</p><p>Megalencephaly (MEG). In some instances, MEG (with or without ventriculomegaly) is detected prenatally on ultrasound examination [<a class="bk_pop" href="#pik3ca-overgrowth.REF.claytonsmith.1997.291">Clayton-Smith et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.vogels.1998.245">Vogels et al 1998</a>,<a class="bk_pop" href="#pik3ca-overgrowth.REF.robertson.2000.1">Robertson et al 2000</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.nyberg.2005.129">Nyberg et al 2005</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.coste.2012.917">Coste et al 2012</a>]. More than 90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children have <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> MEG that is universally progressive [<a class="bk_pop" href="#pik3ca-overgrowth.REF.claytonsmith.1997.291">Clayton-Smith et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.vogels.1998.245">Vogels et al 1998</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.robertson.2000.1">Robertson et al 2000</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.nyberg.2005.129">Nyberg et al 2005</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.coste.2012.917">Coste et al 2012</a>]. A few affected children have normal head size at birth but develop progressive MEG within the first year of life [<a class="bk_pop" href="#pik3ca-overgrowth.REF.moore.1997.67">Moore et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</p><p>In a review of 21 children with MCAP syndrome and other published and unpublished cases [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>; Author, unpublished data], birth occipitofrontal circumference (OFC) typically ranges from +2 to +7 standard deviations (SDs) above the mean for gestational age. Most children cross OFC percentiles during the first year of life and, although head growth may level off in early childhood, it typically remains at +3 SD or more above the mean.</p><p>In children who have undergone neurosurgical shunting for obstructive ventriculomegaly or hydrocephalus, head growth noticeably continues at an accelerated pace, indicating the primary nature of MEG in this syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.moore.1997.67">Moore et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007a.296">Conway et al 2007a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</p><p>Adult OFCs range from +2 to as large as +10 SDs above the mean.</p><p>The process of generalized brain overgrowth may be accompanied by secondary overgrowth of specific brain structures such as the ventricles, corpus callosum, and cerebellum resulting in ventriculomegaly, a markedly thick corpus callosum, and cerebellar tonsillar ectopia with crowding of the posterior fossa, respectively [<a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</p><p><b>Neurosurgical complications.</b> Given the significant MEG, most individuals with MCAP syndrome undergo brain imaging shortly after birth or within the first year of life leading to early identification of key neuroimaging features discussed below [<a class="bk_pop" href="#pik3ca-overgrowth.REF.vogels.1998.245">Vogels et al 1998</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.nyberg.2005.129">Nyberg et al 2005</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007a.296">Conway et al 2007a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mart_nezlage.2010.13">Mart&#x000ed;nez-Lage et al 2010</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>]. (See <a class="figpopup" href="/books/NBK153722/figure/pik3ca-overgrowth.F4/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthF4" rid-ob="figobpik3caovergrowthF4">Figure 4</a>.)</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Ventriculomegaly and hydrocephalus.</b> Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children have evidence of ventricular dilatation or ventriculomegaly on early brain imaging. In a large review of the neuroimaging findings in MCAP syndrome, 37 out of 65 (56%) children had ventriculomegaly ranging from mild to frank hydrocephalus, with or without cerebellar tonsillar ectopia [<a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>]. While it is unclear whether or not ventriculomegaly is obstructive in all these individuals, more than half of affected children undergo ventricular shunting, usually within the first year of life.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Cerebellar tonsillar ectopia (CBTE).</b> A large cerebellum, combined with a small posterior fossa leading to cerebellar tonsillar ectopia, or a Chiari malformation, and syringomyelia are potentially common complications in MCAP syndrome. Fifteen of 65 reported cases have evidence of CBTE with or without herniation [<a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>]. The degree of ectopia is best objectively assessed by measuring the distance of the cerebellar tonsils below the foramen magnum. Unlike ventriculomegaly, CBTE is rarely <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> in MCAP syndrome.</div><div class="half_rhythm">The symptoms of a Chiari malformation in children are often difficult to assess and include neck pain or headache, motor weakness, sensory changes, vision problems, swallowing difficulties, or behavioral changes. Infants may have difficulty swallowing, irritability, excessive drooling, or breathing problems, especially central apnea. In two individuals spontaneous "resolution" of CBTE on follow-up imaging was attributed to disproportionately accelerated skull overgrowth [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</div></li></ul><p><b>Cortical brain malformation and polymicrogyria (PMG).</b> While few reports of PMG with MCAP syndrome appeared in the early literature, it is now clear that it may be present in more than 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children [<a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.gripp.2009.868">Gripp et al 2009</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>; Authors, unpublished data]. The most common type of PMG in MCAP syndrome is bilateral perisylvian PMG, although other types including bilateral frontal and focal PMG occur. PMG broadly, and bilateral perisylvian PMG in particular, increase the risk for: epilepsy; oral motor weakness leading to feeding, swallowing and expressive language difficulties; developmental delay; and tone abnormalities.</p><p>Younger children with PMG (specifically of the frontal region) have hypotonia, are not spastic, and may have pseudobulbar problems, whereas older children often have spasticity and pseudobulbar problems [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</p><p><b>Intellectual disability.</b> Most individuals with MCAP syndrome have some degree of intellectual disability, although the degree is broad and ranges from mild learning disability to severe disability. Most have mild-moderate delays yet continue to make steady developmental progress, albeit at a slower rate than average. A few (&#x0003c;10%) have severe handicaps. The range of expected milestone acquisition has not yet been clarified in MCAP.</p><p>The degree of intellectual disability appears to be mostly related to the presence and severity of seizures, cortical dysplasia (e.g., PMG), and hydrocephalus. Gross motor delays are probably caused by multiple factors in the individual patient and include MEG, cortical brain malformations, hypotonia, limb asymmetry or overgrowth, and connective tissue dysplasia.</p><p><b>Autistic features and other behavioral abnormalities.</b> A subset of children (6/21) with MCAP syndrome have autism or autistic features [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>], suggesting that autism may be part of the neurocognitive profile of a minority of individuals with this MEG syndrome, similar to <i>PTEN</i>-related disorders [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mcbride.2010.137">McBride et al 2010</a>]. Other behavioral abnormalities seen in one or a few children include attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive tendencies, and anxiety-related issues.</p><p><b>Seizures.</b> Approximately 30% of individuals with MCAP syndrome have seizures. In some children, seizures are mild and consist of a few episodes that do not warrant long-term antiepileptic drug therapy. In others, seizures may be severe, correlating strongly with the presence of severe and more diffuse cortical dysgenesis, particularly PMG [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lapunzina.2004.45">Lapunzina et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</p><p>Children with MCAP syndrome and hemimegalencephaly usually have more severe seizures of earlier onset and poor neurocognitive outcome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.barkovich.2005.1873">Barkovich et al 2005</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>].</p><p><b>Tone abnormalities.</b> Hypotonia, and particularly neonatal hypotonia, is a frequent finding in MCAP syndrome. This may be primarily central (secondary to MEG and associated brain abnormalities) and partially peripheral (secondary to mild connective tissue dysplasia resulting in lax joints).</p><p><b>Vascular malformations.</b> The majority of children with MCAP syndrome have a capillary type of vascular malformation. Most common are capillary malformations in the mid-facial region (forehead, upper lip and philtrum; such as a persistent nevus flammeus) and generalized or extensive capillary malformations, resembling cutis marmorata. While these lesions may fade as the child grows older, they often persist to some degree and appearance may vary with changes in temperature or temperament [<a class="bk_pop" href="#pik3ca-overgrowth.REF.toriello.2007.3009">Toriello &#x00026; Mulliken 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al 2009</a>].</p><p>Other vascular abnormalities seen less frequently include infantile hemangiomas (cutaneous, subcutaneous, visceral) that may or may not involute later on in life, dilated and prominent cutaneous and intracranial venous networks, aberrant vasculature in various locations (such as periorbital and cardiac vessels), venous malformations, and vascular rings. Some children undergo laser therapy of cutaneous lesions with no observed recurrences [<a class="bk_pop" href="#pik3ca-overgrowth.REF.claytonsmith.1997.291">Clayton-Smith et al 1997</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.yano.2001.149">Yano &#x00026; Watanabe 2001</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.akcar.2004.261">Akcar et al 2004</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.gripp.2009.868">Gripp et al 2009</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al 2009</a>; <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>; Authors, unpublished data].</p><p>Notably, some individuals with MCAP syndrome have experienced venous thrombosis, and one individual had a large tufted angioma of the shoulder complicated by Kasabach-Merritt syndrome in infancy [<a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al 2009</a>].</p><p><b>Somatic overgrowth and asymmetry.</b> Most children with MCAP syndrome are large (or macrosomic) at birth [<a class="bk_pop" href="#pik3ca-overgrowth.REF.claytonsmith.1997.291">Clayton-Smith et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.moore.1997.67">Moore et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lapunzina.2004.45">Lapunzina et al 2004</a>]. Data suggest that height and weight normalize in most children; however, postnatal growth delay due to growth hormone deficiency of unknown cause has been reported in a few children [<a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007a.296">Conway et al 2007a</a>].</p><p>Some individuals manifest focal or segmental overgrowth of a limb or a few digits, resulting in somatic asymmetry. This focal overgrowth is milder than that in CLOVES syndrome. Furthermore, it is <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> and not relentlessly progressive, unlike that in Proteus syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.biesecker.1999.389">Biesecker et al 1999</a>]. Focal or unilateral skeletal overgrowth resulting in leg-length discrepancy is common in MCAP syndrome.</p><p><b>Digital anomalies.</b> The most common digital anomaly in MCAP syndrome is cutaneous syndactyly, particularly of toes 2-3 or fingers 3-4. Postaxial polydactyly is also common and some individuals have both (i.e., polysyndactyly). Other less common digital anomalies include sandal-gap (increased gap between) toes, broad thumbs and toes, and hypoplastic and deep-set nails.</p><p><b>Connective tissue dysplasia.</b> Individuals with MCAP syndrome manifest varying degrees of connective tissue dysplasia. The most prominent feature of this is soft and redundant (often described as "doughy") subcutaneous tissue. Variable degrees of skin hyperelasticity, joint hypermobility, and ligamentous laxity may also be evident on close examination. These changes are often more severe when coexistent with extensive capillary malformations. Combined with generalized hypotonia and the brain abnormalities, they contribute to early gross motor delays.</p><p>In a few cases, connective tissue involvement leads to <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> dislocation of the joints, including the hips or knees.</p><p><b>Facial features.</b> The most striking facial feature in individuals with MCAP syndrome is frontal bossing secondary to significant MEG. The face maybe rounded due to overgrowth or increased subcutaneous tissue, or asymmetric due to focal somatic overgrowth. Coarsening of the facial features with prominent lips is common; characteristic ear abnormalities are seen less often [<a class="bk_pop" href="#pik3ca-overgrowth.REF.gripp.2009.868">Gripp et al 2009</a>]. No other <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> facial features are consistently observed [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lapunzina.2004.45">Lapunzina et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mart_nezglez.2010.3101">Mart&#x000ed;nez-Glez et al 2010</a>].</p><p><b>Cardiovascular abnormalities.</b> A few children with MCAP syndrome have <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> structural heart disease, such as a single ventricular septal defect (VSD) or atrial septal defect (ASD), of unknown pathogenesis.</p><p>More importantly, complex cardiovascular abnormalities involving structural and vascular lesions have been seen in a few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, including combined ASD with dilated left atrium and mitral valve regurgitation [<a class="bk_pop" href="#pik3ca-overgrowth.REF.yano.2001.149">Yano &#x00026; Watanabe 2001</a>]; ASD with a giant atrial septal aneurysm [<a class="bk_pop" href="#pik3ca-overgrowth.REF.akcar.2004.261">Akcar et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.dinleyici.2004.366">Dinleyici et al 2004</a>]; ASD, VSD, right-sided aortic arch with an aberrant subclavian artery [<a class="bk_pop" href="#pik3ca-overgrowth.REF.gripp.2009.868">Gripp et al 2009</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>]; two muscular VSDs and a vascular ring [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>]; and tetralogy of Fallot [<a class="bk_pop" href="#pik3ca-overgrowth.REF.ercan.2013.115">Ercan et al 2013</a>].</p><p>Arrhythmias in the fetus or newborn have been reported, overlapping with those above, including atrial flutter in three individuals [<a class="bk_pop" href="#pik3ca-overgrowth.REF.yano.2001.149">Yano &#x00026; Watanabe 2001</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>] and supraventricular tachycardia in two [<a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.kuint.2012.384">Kuint et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>]. Cardiorespiratory arrest has occurred in some secondary to these heart abnormalities.</p><p>Furthermore, four children with complex <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart disease and/or cardiac rhythm abnormalities experienced sudden cardiorespiratory arrest (ages 17 days &#x02013; 19 months) presumably secondary to these cardiac abnormalities [<a class="bk_pop" href="#pik3ca-overgrowth.REF.claytonsmith.1997.291">Clayton-Smith et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.yano.2001.149">Yano &#x00026; Watanabe 2001</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.akcar.2004.261">Akcar et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007a.296">Conway et al 2007a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.kuint.2012.384">Kuint et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.ercan.2013.115">Ercan et al 2013</a>].</p><p><b>Gastrointestinal problems.</b> Individuals with MCAP syndrome occasionally have feeding and swallowing difficulties due to a number of factors, including the underlying brain abnormalities, particularly PMG, poor tone, and gastroesophageal reflux disease (GERD). Furthermore, two individuals with MCAP syndrome and intestinal lymphangiectasias have been reported, suggesting the association of MCAP with lymphatic abnormalities [<a class="bk_pop" href="#pik3ca-overgrowth.REF.thong.1999.283">Thong et al 1999</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.m_garban_.2003.184">M&#x000e9;garban&#x000e9; et al 2003</a>].</p><p><b>Tumors.</b> Many benign and a few malignant tumors have been reported in MCAP syndrome. Malignant tumors seen in individuals with MCAP syndrome include the following:</p><ul><li class="half_rhythm"><div>Wilms tumor in two children (ages 10 months and 4 years) [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lapunzina.2004.45">Lapunzina et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al 2009</a>]</div></li><li class="half_rhythm"><div>Leukemia in an 18-year-old [<a class="bk_pop" href="#pik3ca-overgrowth.REF.moore.1997.67">Moore et al 1997</a>]</div></li><li class="half_rhythm"><div>Meningiomas in two children (ages 21 months and 5 years) [<a class="bk_pop" href="#pik3ca-overgrowth.REF.moore.1997.67">Moore et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.conway.2007b.2981">Conway et al 2007b</a>]</div></li></ul><p>Overall, the risk for malignancy in MCAP syndrome appears to be lower than in <a href="/books/n/gene/bws/">Beckwith-Wiedemann syndrome</a>, as there are reports of malignancy in only three of approximately 150 (2%) individuals. Note: By adding meningiomas, the risk increases marginally to 5/150 (3.3%) [<a class="bk_pop" href="#pik3ca-overgrowth.REF.debaun.1998.398">DeBaun &#x00026; Tucker 1998</a>].</p><p>The most common benign tumors in MCAP are vascular, described variably as (cavernous) hemangiomas, angiomata, angiomyolipomas, and vascular masses [<a class="bk_pop" href="#pik3ca-overgrowth.REF.claytonsmith.1997.291">Clayton-Smith et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.moore.1997.67">Moore et al 1997</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mart_nezglez.2010.3101">Mart&#x000ed;nez-Glez et al 2010</a>]. While most common in skin or subcutaneous tissue, hemangiomas have been described in viscera and skull. Several individuals with MCAP also have lipomas that typically remain stable in size, and at least one individual had multiple lipomas [<a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al 2009</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</p><p>See Molecular Genetics, <a href="#pik3ca-overgrowth.Cancer_and_Benign_Tumo">Cancer and Benign Tumors</a> for additional information.</p></div><div id="pik3ca-overgrowth.CLOVES_Syndrome"><h4>CLOVES Syndrome</h4><p>CLOVES syndrome (<i>c</i>ongenital <i>l</i>ipomatous asymmetric <i>o</i>vergrowth of the trunk, lymphatic, capillary, venous, and combined-type <i>v</i>ascular malformations, <i>e</i>pidermal nevi, <i>s</i>keletal and <i>s</i>pinal anomalies) is a severe overgrowth disorder characterized by focal and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> lipomatous overgrowth, various vascular and lymphatic malformations, epidermal nevi, acral and musculoskeletal abnormalities, and renal anomalies, among other minor features.</p><p><b>Somatic overgrowth.</b> Newborns typically have complex lipomatous overgrowth of the thoracic and abdominal wall, often with overlying vascular malformations. Variable contiguous extension to the groin, retroperitoneum, mediastinum, and gluteal area may occur. This overgrowth varies in extent and can be unilateral or bilateral at onset. In some cases, the lipomatous overgrowth or mass is identified prenatally on ultrasound examination. Overlying vascular malformations can be capillary, lymphatic, venous, or arteriovenous [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>].</p><p>Other manifestations of overgrowth include symmetric overgrowth with splaying of the feet, macrodactyly, and plantar or palmar overgrowth which results in wrinkling of the overlying palmar or plantar skin distinct from the classic cutaneous connective tissue nevi (CCTN) in <a href="/books/n/gene/proteus/">Proteus syndrome</a>.</p><p><b>Vascular malformations and epidermal nevi.</b> Both low-flow (capillary, venous, and lymphatic) and high-flow (arteriovenous) malformations occur.</p><p>Lymphatic malformations and vesicles within the classic truncal lipomatous overgrowth may occur, and can be complicated by recurrent infections.</p><p>High-flow lesions (arteriovenous malformations) within and around the lipomatous mass and in the paraspinal regions are common. These lesions can be associated with severe sequelae (see <a href="#pik3ca-overgrowth.Clinical_Description">Clinical Description</a>, <b>Neurologic and spinal complications</b>) [<a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2011.1812">Alomari et al 2011</a>].</p><p>Venous malformations (phlebectasia), typically of the thoracic or central veins and prominent superficial veins have been reported. Deep vein thrombosis and pulmonary embolism are potentially fatal complications [<a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2010.459">Alomari et al 2010</a>].</p><p>Epidermal nevi are common, particularly when overlying lipomatous overgrowth [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>].</p><p><b>Musculoskeletal and acral malformations.</b> Skeletal anomalies can be markedly deforming. The most common is progressive scoliosis ranging from mild to severe [<a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009b.294">Alomari 2009b</a>].</p><p>Additional abnormalities include abnormal vertebral bodies, chondromalacia patellae, knee dislocation, wide hands and feet, wide sandal gap, macrodactyly, and talipes equinovarus. Marked bony overgrowth can result in significant leg length discrepancy necessitating surgery. Hip dysplasia requiring surgical intervention has been reported [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.klein.2012.1690">Klein et al 2012</a>].</p><p>Abnormalities seen occasionally include pectus excavatum and postaxial polydactyly [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.klein.2012.1690">Klein et al 2012</a>].</p><p><b>Neurologic and spinal complications.</b> Direct extension of the lipomatous overgrowth into the paraspinal and intraspinal spaces is associated with high risks for compression of the cord, thecal sac, and nerve roots.</p><p>Some individuals have debilitating spinal myopathy due to the fast-flow spinal-paraspinal vascular lesions [<a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2011.1812">Alomari et al 2011</a>]. Additionally, tethered cord, vertebral anomalies, neural tube defects, and spasticity are common.</p><p>Individuals with CLOVES syndrome have variable degrees of intellectual disability [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>]. Their brain malformations overlap with those in MCAP syndrome: macrocephaly with polymicrogyria and seizures resulting in death at age nine weeks [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>]; hemimegalencephaly with agenesis of the corpus callosum [<a class="bk_pop" href="#pik3ca-overgrowth.REF.gucev.2008.2688">Gucev et al 2008</a>]; and Chiari malformations [<a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2011.1812">Alomari et al 2011</a>].</p><p><b>Renal and other visceral complications.</b> Renal agenesis/hypoplasia, as well as renal calculi and hematuria have been seen in individuals with CLOVES syndrome. Other visceral anomalies include splenic lesions and extensive deep retroperitoneal, pelvic fatty and lymphatic malformation [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2011.215">Alomari 2011</a>].</p><p><b>Tumors.</b> Tumors reported in CLOVES syndrome include chorangioma, extradural spinal tumor, hemangioma, and multiple angiomatosis (one each) [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>].</p></div><div id="pik3ca-overgrowth.Fibroadipose_Hyperplas"><h4>Fibroadipose Hyperplasia (FH)</h4><p>Fibroadipose hyperplasia is a severe progressive segmental overgrowth syndrome reported in ten individuals [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>]. This disorder overlaps clinically and molecularly with CLOVES syndrome.</p><p><b>Segmental overgrowth.</b> FH is characterized by severe segmental overgrowth of subcutaneous, muscular, and visceral fibroadipose tissue with skeletal overgrowth resulting in asymmetry. The extent of overgrowth varied among individuals, but was extensive in some and progressed into adulthood. Eight of ten individuals underwent multiple debulking or orthopedic procedures.</p><p>Seven of eight individuals on whom records were available had <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> asymmetric overgrowth. Four had skeletal overgrowth with preserved architecture. Bone age, when assessed, was normal.</p><p>Notably, four individuals had marked lipoatrophy in areas not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by overgrowth without evidence of hypoglycemia or insulin resistance.</p><p><b>Other abnormalities</b> include the following (summarized in <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.classic_features_of/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTclassicfeaturesof" rid-ob="figobpik3caovergrowthTclassicfeaturesof">Table 2</a>):</p><ul><li class="half_rhythm"><div>Cutaneous capillary vascular malformations (2 individuals)</div></li><li class="half_rhythm"><div>Testicular or epididymal abnormalities (3 individuals)</div></li><li class="half_rhythm"><div>Epidermal nevi (2 individuals)</div></li><li class="half_rhythm"><div>Polydactyly (1 individual)</div></li></ul><p>All ten individuals with FH had normal intellect.</p></div></div><div id="pik3ca-overgrowth.GenotypePhenotype_Corr"><h3>Genotype-Phenotype Correlations</h3><p>Analysis of <i>PIK3CA</i> pathogenic variants in neoplastic tissues of individuals without <i>PIK3CA</i>-associated segmental overgrowth has identified four mutational hot spots (see <a href="#pik3ca-overgrowth.Molecular_Genetics">Molecular Genetics</a> and <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">Table 4</a>).</p><p>Interestingly, preliminary <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> analysis of individuals with <i>PIK3CA</i>-associated segmental overgrowth suggests that MCAP syndrome is primarily associated with <i>PIK3CA</i> pathogenic variants not commonly identified in tumors, whereas hemimegalencephaly, CLOVES syndrome, and fibroadipose hyperplasia are associated with <i>PIK3CA</i> pathogenic variants at the cancer-related mutational hot spots (see <a href="#pik3ca-overgrowth.Molecular_Genetics">Molecular Genetics</a>, <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">Table 4</a>, and <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.common_cancerrelated/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTcommoncancerrelated" rid-ob="figobpik3caovergrowthTcommoncancerrelated">Table 5</a>).</p></div><div id="pik3ca-overgrowth.Penetrance"><h3>Penetrance</h3><p>Degree of incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> cannot be assessed in a mosaic genetic disorder.</p></div><div id="pik3ca-overgrowth.Nomenclature"><h3>Nomenclature</h3><p><b>Megalencephaly-capillary malformation</b> (<b>MCAP) syndrome</b> has been renamed several times as understanding of its distinguishing features (particularly the cutaneous vascular anomalies) evolved.</p><ul><li class="half_rhythm"><div>Originally termed the macrocephaly-cutis marmorata telangiectatica congenita (M-CMTC) syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.moore.1997.67">Moore et al 1997</a>], the name was later shortened to "macrocephaly-cutis marmorata" (M-CM) syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.cohen.2003.49">Cohen 2003</a>].</div></li><li class="half_rhythm"><div>When it was recognized that the terms used for the characteristic cutaneous vascular anomalies were misnomers, the term "macrocephaly-capillary malformation" syndrome was adopted [<a class="bk_pop" href="#pik3ca-overgrowth.REF.toriello.2007.3009">Toriello &#x00026; Mulliken 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.wright.2009.287">Wright et al 2009</a>].</div></li><li class="half_rhythm"><div>The name was further refined to "megalencephaly-capillary malformation" (MCAP) syndrome, emphasizing that this is true megalencephaly rather than "macrocephaly," a less specific term denoting a large head due to numerous causes [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</div></li></ul></div><div id="pik3ca-overgrowth.Prevalence"><h3>Prevalence</h3><p>Prevalence of <i>PIK3CA</i>-associated overgrowth is difficult to estimate due to variation in ascertainment and the broad phenotypic spectrum. Many individuals have atypical or mild phenotypes leading to misidentification.</p><p><i>PIK3CA</i>-associated overgrowth has been reported in individuals of various ethnic backgrounds.</p><p>More than 150 individuals have been reported with MCAP syndrome. Some previously reported as Proteus syndrome or KTS undoubtedly had this disorder; therefore, MCAP syndrome is believed to be a common overgrowth syndrome.</p></div></div><div id="pik3ca-overgrowth.Genetically_Related_Al"><h2 id="_pik3ca-overgrowth_Genetically_Related_Al_">Genetically Related (Allelic) Disorders</h2><p><b>Isolated macrodactyly.</b> Mosaicism for <i>PIK3CA</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants has been identified in individuals with type I macrodactyly, the most common form of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> limb overgrowth. These individuals lack vascular malformations and overgrowth involving other body parts [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rios.2013.444">Rios et al 2013</a>]. Notably, the mosaic <i>PIK3CA</i> pathogenic variants in these individuals were identified in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> peripheral nerve cells and were absent from blood.</p><p><b>Klippel-Trenaunay syndrome (KTS).</b> Mosaicism for a <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in three of 15 individuals with a diagnosis of KTS (but on whom no clinical details were provided), suggesting a causal relationship between a KTS-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and <i>PIK3CA</i> [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>]. Note: It can be questioned whether these individuals had bona fide KTS because of the lack of accompanying clinical details.</p><p><b>Cowden syndrome.</b> Recently, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>PIK3CA</i> pathogenic variants were identified in eight individuals with a clinical diagnosis of Cowden syndrome and "Cowden-like" features suggesting that germline <i>PIK3CA</i> pathogenic variants are associated with these phenotypes [<a class="bk_pop" href="#pik3ca-overgrowth.REF.orloff.2013.76">Orloff et al 2013</a>]. See <a href="/books/n/gene/phts/"><i>PTEN</i> Tumor Hamartoma Syndrome</a>.</p></div><div id="pik3ca-overgrowth.Differential_Diagnosis"><h2 id="_pik3ca-overgrowth_Differential_Diagnosis_">Differential Diagnosis</h2><p>A number of overgrowth and megalencephaly disorders overlap with the <i>PIK3CA</i>-associated segmental overgrowth syndromes, including the following.</p><p><b>Hemimegalencephaly (HMEG)</b> is characterized by enlargement and dysplasia of all or part of a cerebral hemisphere. In addition to CLOVES syndrome (discussed in this <i>GeneReview</i>), it can be <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> but has also been reported in association with disorders of focal somatic overgrowth and/or vascular malformations such as Klippel Trenauany syndrome, hypomelanosis of Ito, <a href="/books/n/gene/proteus/">Proteus syndrome</a>, linear nevus sebaceous syndrome, <a href="/books/n/gene/tuberous-sclerosis/">tuberous sclerosis complex</a>, and <a href="/books/n/gene/bcns/">nevoid basal cell carcinoma</a> [<a class="bk_pop" href="#pik3ca-overgrowth.REF.abdelhalim.2003.534">Abdelhalim et al 2003</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.sharma.2009.12">Sharma et al 2009</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.pavlidis.2012.332">Pavlidis et al 2012</a>]. Besides <i>PIK3CA</i>, mosaic pathogenic variants in other genes of the PI3K-AKT pathway (see <a href="#pik3ca-overgrowth.Molecular_Pathogenesis">Molecular Pathogenesis</a>), including <i>AKT3</i> and <i>MTOR,</i> have been identified in brain tissue from individuals with HMEG [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lee.2012.941">Lee et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.poduri.2012.41">Poduri et al 2012</a>].</p><p><a href="/books/n/gene/mpph/"><b>Megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome</b></a> was first described in 2004 and has since been reported in 29 individuals [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2004.353">Mirzaa et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.colombani.2006.466">Colombani et al 2006</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.garavelli.2007.200">Garavelli et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.tohyama.2007.148">Tohyama et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.pisano.2008.916">Pisano et al 2008</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.tore.2009.1620">Tore et al 2009</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.osterling.2011.370">Osterling et al 2011</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.kariminejad.2013.651">Kariminejad et al 2013</a>]. This disorder is characterized by significant, and most often <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>, megalencephaly (MEG), bilateral perisylvian polymicrogyria (PMG), postaxial polydactyly, and an increased risk for hydrocephalus. While its four core features, and primarily the neuroimaging manifestations, overlap with MCAP syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.gripp.2009.868">Gripp et al 2009</a>], MPPH syndrome can be primarily distinguished by the absence of vascular malformations, focal somatic overgrowth, and connective tissue dysplasia [<a class="bk_pop" href="#pik3ca-overgrowth.REF.verkerk.2010.1488">Verkerk et al 2010</a>]. <i>De novo</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>PIK3R2</i> and <i>AKT3</i>, two other core components of the PI3K-AKT pathway, have been identified in MPPH syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>].</p><p><b>Klippel-Trenaunay syndrome (KTS)</b> is characterized by disproportionate growth disturbance combined with cutaneous capillary, lymphatic, and venous malformations. KTS typically involves the lower extremities but may affect the upper extremities and may be bilateral. The findings are typically focal and usually spare the craniofacial region, distinguishing it from the more generalized overgrowth observed in <i>PI3KCA</i>-related segmental overgrowth syndromes [<a class="bk_pop" href="#pik3ca-overgrowth.REF.oduber.2011.262">Oduber et al 2011</a>].</p><p><b>Bannayan-Riley-Ruvalcaba syndrome (BRRS),</b> the most severe end of the <a href="/books/n/gene/phts/"><i>PTEN</i>-related overgrowth spectrum</a>, is characterized by macrocephaly, developmental delay, lipomatosis, intestinal hamartomatous polyposis, and pigmented macules of the penis. While capillary malformations have been seen in BRRS, they are typically isolated and not similar to the capillary malformations in MCAP syndrome. Furthermore, BRRS lacks the significant overgrowth (particularly the truncal lipomatous overgrowth), acral deformities, and other characteristic features of CLOVES syndrome and fibroadipose hyperplasia. BRRS is caused by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>PTEN</i>. Most individuals with BRRS have normal intelligence.</p><p><a href="/books/n/gene/proteus/"><b>Proteus syndrome</b></a><b>,</b> a severe overgrowth syndrome, is associated with disproportionate and asymmetric postnatal somatic overgrowth including skeletal overgrowth, cerebriform connective tissue nevi (CCTN), epidermal nevi, dysregulated adipose tissue, and vascular malformations. Proteus syndrome can be primarily distinguished from CLOVES syndrome and fibroadipose hyperplasia by the postnatal onset of overgrowth. Furthermore, Proteus syndrome lacks the characteristic truncal fatty-vascular mass, spinal paraspinal fast-flow lesions and the acral abnormalities characteristic of CLOVES syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.biesecker.1999.389">Biesecker et al 1999</a>]. Severely deforming and progressive skeletal overgrowth and poor prognosis occur in both disorders. Mosaic pathogenic variants in <i>AKT1</i> were identified in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues of individuals with Proteus syndrome [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2011.611">Lindhurst et al 2011</a>].</p><p><b>Hemihyperplasia-multiple lipomatosis (HHML)</b>
<b>syndrome</b>, a distinct milder form of overgrowth, is characterized by moderate somatic asymmetry and overgrowth with subcutaneous lipomas and occasional vascular malformations, but lacks deep vascular malformations, epidermal nevi, cerebriform connective tissue nevi (CCTN), and hyperostosis. HHML syndrome may overlap with CLOVES syndrome given that overgrowth can be progressive and spinal complications and scoliosis have been reported [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>].</p><p><b>SOLAMEN syndrome</b> is characterized by atypical features of Cowden syndrome including segmental overgrowth, lipomatosis, arteriovenous malformation, and epidermal nevi. It is also associated with tumors such as ovarian cystadenoma, multiple breast tumors, and thyroid adenomas. Fibrocystic breast disease, gingival papules, and multinodular goiter have also been reported. SOLAMEN syndrome results from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> inactivation of <i>PTEN</i> (type 2 <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a>), restricted to the atypical lesions [<a class="bk_pop" href="#pik3ca-overgrowth.REF.caux.2007.767">Caux et al 2007</a>]. (See <a href="/books/n/gene/phts/"><i>PTEN</i> Hamartoma Tumor Syndrome</a>.)</p></div><div id="pik3ca-overgrowth.Management"><h2 id="_pik3ca-overgrowth_Management_">Management</h2><div id="pik3ca-overgrowth.Evaluations_Following"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual with <i>PIK3CA</i>-associated segmental overgrowth, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>A thorough history to identify key features of <i>PIK3CA</i>-associated segmental overgrowth</div></li><li class="half_rhythm"><div>A physical examination including a thorough skin, cardiac, abdominal, and musculoskeletal evaluation, as well as a detailed neurologic assessment</div></li><li class="half_rhythm"><div>Investigations to detect abnormalities before they result in significant morbidity/mortality:</div><ul><li class="half_rhythm"><div>Baseline brain and spinal cord imaging, especially in children with hemimegalencephaly (HMEG) and MCAP syndrome for early detection of cortical dysplasia, ventriculomegaly, and cerebellar tonsillar ectopia.</div></li><li class="half_rhythm"><div>A cardiovascular assessment including a baseline echocardiogram and electrocardiogram to evaluate for cardiovascular malformations and rhythm abnormalities</div></li><li class="half_rhythm"><div>A baseline renal ultrasound to evaluate for structural renal abnormalities</div></li><li class="half_rhythm"><div>Surgical and orthopedic referrals for individuals suspected of having CLOVES syndrome or fibroadipose hyperplasia, and individuals with MCAP syndrome with focal somatic overgrowth or leg-length discrepancy</div></li></ul></li></ul></div><div id="pik3ca-overgrowth.Treatment_of_Manifesta"><h3>Treatment of Manifestations</h3><p>Patients with <i>PIK3CA</i>-associated segmental overgrowth benefit from a coordinated and multidisciplinary clinical approach tailored to the individual's specific needs and manifestations.</p><p>Referral to the appropriate specialist(s) is recommended for the following findings:</p><ul><li class="half_rhythm"><div>Significant or lipomatous segmental overgrowth: referral to a surgeon and/or thoracic surgeon (when lipomatous overgrowth involves the trunk)</div></li><li class="half_rhythm"><div>Leg-length discrepancy secondary to segmental somatic overgrowth</div></li><li class="half_rhythm"><div>Cardiac abnormalities (i.e., structural cardiovascular disease and arrhythmias)</div></li><li class="half_rhythm"><div>Renal abnormalities</div></li><li class="half_rhythm"><div>Intellectual disability and/or difficulties with learning, behavior, or speech, or motor difficulties</div></li><li class="half_rhythm"><div>Speech, swallowing, and feeding difficulties</div></li></ul><p><b>Neurologic and neurosurgical manifestations</b></p><ul><li class="half_rhythm"><div><b>MCAP syndrome.</b> Findings warranting neurosurgical referral include rapidly enlarging OFC, obstructive hydrocephalus, symptoms of raised intracranial pressure, and progressive or symptomatic cerebellar tonsillar ectopia (CBTE) or Chiari malformation. Early treatment of hydrocephalus may reduce the risk for progressive CBTE, but data are lacking to determine the most appropriate neurosurgical management. In recent years, favorable outcomes have been observed with ventriculostomy of the third ventricle (rather than insertion of a ventriculo-peritoneal shunt), suggesting that the neurosurgical management of hydrocephalus in MCAP syndrome is evolving.</div></li><li class="half_rhythm"><div><b>HMEG.</b> Individuals are at risk for severe early-onset epilepsy, focal neurologic signs such as hemiparesis, and severe intellectual disability. Epilepsy and intellectual disability may be improved by hemispherectomy [<a class="bk_pop" href="#pik3ca-overgrowth.REF.di_rocco.2006.852">Di Rocco et al 2006</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.kwan.2008.643">Kwan et al 2008</a>].</div></li><li class="half_rhythm"><div>Individuals with HMEG and MCAP syndrome with polymicrogyria (PMG) are at increased risk for epilepsy; thus, long-term neurologic follow up is warranted, and many require long-term antiepileptic treatment [<a class="bk_pop" href="#pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa et al 2012</a>].</div></li></ul><p><b>Somatic overgrowth, vascular, lymphatic and musculoskeletal manifestations.</b> CLOVES syndrome and fibroadipose hyperplasia (FH) are associated with severe focal overgrowth, vascular malformations, and orthopedic complications with significant morbidities. Prompt diagnosis (by MR/CT and angiography) is warranted. Most individuals undergo (often several) debulking or orthopedic procedures with significant ensuing complications (see <a href="#pik3ca-overgrowth.Surveillance">Surveillance</a>).</p><p>The following are the main treatment considerations in CLOVES syndrome:</p><ul><li class="half_rhythm"><div>The characteristic truncal lipomatous mass infiltrates surrounding tissues and often requires surgical excision. Severe scoliosis, large truncal mass, paraspinal high-flow lesions with spinal cord ischemia, lymphatic malformations, cutaneous vesicles, orthopedic problems of the feet and hands, and central phlebectasia/thromboembolism are examples of significant morbidities that need active or prophylactic medical intervention.</div></li><li class="half_rhythm"><div>Paraspinal and intraspinal extension have significant risk for compression of the cord, thecal sac, and nerve roots, with resultant major neurologic deficits, warranting prompt diagnosis and multidisciplinary care [<a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>].</div></li><li class="half_rhythm"><div>Given the risk for thromboembolism in CLOVES syndrome, appropriate prophylactic measures including anticoagulation and caval filtration, particularly in the perioperative period, are recommended. Central and thoracic phlebectasia in individuals with CLOVES syndrome should be considered an indication for placement of a superior vena cava (SVC) filter.</div></li></ul><p>FH is associated with severe progressive overgrowth of fibrous and adipose tissues. While the severity and natural history varied among reported individuals, thorough surgical and orthopedic evaluations are warranted. Most individuals (8/10) underwent extensive debulking or orthopedic procedures.</p></div><div id="pik3ca-overgrowth.Surveillance"><h3>Surveillance</h3><p><b>MCAP syndrome.</b> Provisional surveillance guidelines include regular follow up, no less than every six months until age six years, and at least yearly thereafter. At each visit, the following are recommended with appropriate testing for any positive finding:</p><ul><li class="half_rhythm"><div>A medical history with attention to:</div><ul><li class="half_rhythm"><div>Childhood cancer</div></li><li class="half_rhythm"><div>Breathing or sleep problems</div></li><li class="half_rhythm"><div>Seizures or other undefined spells, headaches, or new or worsening neurologic symptoms</div></li></ul></li><li class="half_rhythm"><div>A detailed neurologic evaluation</div></li><li class="half_rhythm"><div>Brain MRI. Based on limited retrospective data available, the risk for hydrocephalus, cerebellar tonsillar ectopia, or both with low brain stem or high spinal cord compression, appears to be highest in the first two years. Brain MRI is provisionally recommended every six months from birth to age two years, and annually from age two to six years. In older individuals, the frequency should be based on prior results and clinical findings, with particular attention to apnea or other abnormal patterns of respiration, headaches, changes in gait, or other neurologic problems.</div></li><li class="half_rhythm"><div>Renal ultrasound. Until additional data are available, screening for Wilms tumor following guidelines developed for <a href="/books/n/gene/bws/">Beckwith-Wiedemann syndrome</a> may be considered (i.e., renal ultrasound examination every 3 months until age 8 years).</div></li></ul><p><b>CLOVES syndrome</b></p><ul><li class="half_rhythm"><div>Given the associated morbidities including severe scoliosis, infiltrative lipomatous overgrowth, paraspinal high-flow lesions with spinal cord ischemia, lymphatic malformations, cutaneous vesicles, orthopedic problems, central phlebectasias and thromboembolism, individuals with CLOVES syndrome require surveillance tailored to their specific needs with particular attention to surgical care [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2011.215">Alomari 2011</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2011.1812">Alomari et al 2011</a>].</div></li><li class="half_rhythm"><div>Commonly occurring postoperative complications of surgical excision of the truncal lipomatous mass include recurrence, hypervascularity, and infiltrative growth. Therefore, diligent surgical care and monitoring are recommended.</div></li></ul><p><b>Fibroadipose hyperplasia.</b> Data regarding the natural history of fibroadipose hyperplasia are limited. However, given the extensive degree of somatic overgrowth in most individuals, the same surveillance guidelines for CLOVES are tentatively recommended for individuals with FH [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>].</p></div><div id="pik3ca-overgrowth.Evaluation_of_Relative"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#pik3ca-overgrowth.Related_Genetic_Counse">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="pik3ca-overgrowth.Therapies_Under_Invest"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="pik3ca-overgrowth.Genetic_Counseling"><h2 id="_pik3ca-overgrowth_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="pik3ca-overgrowth.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>PIK3CA</i>-associated segmental overgrowth is not known to be inherited. No confirmed vertical transmission or sib recurrence has been reported.</p><p>The molecular data show that 21 of 24 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for pathogenic variants in <i>PIK3CA</i> [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>], suggesting that mutation occurred post-fertilization in one cell of the multicellular embryo. Two individuals with MCAP syndrome had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PIK3CA</i> [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>]. The third had only one tissue tested with inconclusive results.</p></div><div id="pik3ca-overgrowth.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> No parent of a child with <i>PIK3CA</i>-associated segmental overgrowth has had any significant, distinctive manifestations of the disorder nor would such a finding be expected, given the somatic mutational mechanism of these disorders.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs of a proband with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PIK3CA</i> would be expected to be the same as in the general population.</p><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Reproductive outcome data on adults with <i>PIK3CA</i>-associated segmental overgrowth are limited; there are no instances of vertical transmission of these disorders. While adults with MCAP syndrome, CLOVES syndrome, and fibroadipose hyperplasia have been reported, the developmental outcome of individuals with hemimegalencephaly (HMEG) is poor.</div></li><li class="half_rhythm"><div>All but three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with MCAP syndrome had <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PIK3CA</i>, suggesting that mutation occurred post-fertilization in one cell of the multicellular embryo. Therefore the risk for transmission to offspring is expected to be less than 50%.</div></li><li class="half_rhythm"><div>Two individuals with MCAP syndrome had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PIK3CA</i> [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>]; therefore, offspring of these individuals have a 50% risk of inheriting the <i>PIK3CA</i> pathogenic variant.</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members is the same as that of the general population.</p></div><div id="pik3ca-overgrowth.Related_Genetic_Counse"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> mosaic <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> This is a relatively new area for clinical genetics as only a small (albeit growing) number of disorders is known to be caused by this genetic mechanism.</p><p>Counseling for <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> in <i>PIK3CA</i>-associated segmental overgrowth should emphasize that, while no pregnancy is at zero risk, all evidence suggests that the risk for recurrence is not increased, compared to the general population. The rare families with MCAP syndrome caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should be counseled regarding the theoretic risk for parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>, which is estimated at less than 1%.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="pik3ca-overgrowth.Prenatal_Testing"><h3>Prenatal Testing</h3><p>Because <i>PIK3CA</i>-associated segmental overgrowth is not inherited, family members are not known to be at increased risk of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> is usually not indicated for family members. However, low-level <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> may theoretically be present in a parent of a child with a germline <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal diagnosis, either through a clinical laboratory or a laboratory offering <a class="def" href="/books/n/gene/glossary/def-item/custom-prenatal-testing/">custom prenatal testing</a>, may be an option for such rare families.</p><p>In addition, prenatal testing may be an option for pregnancies identified by ultrasound examination to be at risk for these syndromes.</p><ul><li class="half_rhythm"><div>Findings on ultrasound examination that suggest MCAP syndrome include marked fetal overgrowth and progressive macrocephaly with no indication of maternal hyperglycemia or fetal hyperinsulinism. Other reported fetal ultrasound findings include ventriculomegaly, pleural effusions, polyhydramnios, hydrops, limb asymmetry, and frontal bossing [<a class="bk_pop" href="#pik3ca-overgrowth.REF.nyberg.2005.129">Nyberg et al 2005</a>]. A fetal MRI in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> fetus with megalencephaly and ventriculomegaly revealed diffuse bilateral polymicrogyria and polysyndactyly of one foot [<a class="bk_pop" href="#pik3ca-overgrowth.REF.gripp.2009.868">Gripp et al 2009</a>].</div></li><li class="half_rhythm"><div>Findings on prenatal ultrasound examination in CLOVES syndrome include prenatal overgrowth, lipomatous truncal masses, and vascular or lymphatic malformations [<a class="bk_pop" href="#pik3ca-overgrowth.REF.sapp.2007.2944">Sapp et al 2007</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2009a.1">Alomari 2009a</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.alomari.2011.1812">Alomari et al 2011</a>].</div></li></ul><p><b>Preimplantation genetic diagnosis (PGD)</b>. Because the <i>PIK3CA</i>-associated segmental overgrowth syndromes are not inherited, family members are not known to have an increased risk of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. The authors recognize no potential role for PGD in these syndromes.</p></div></div><div id="pik3ca-overgrowth.Resources"><h2 id="_pik3ca-overgrowth_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>M-CM Network</b></div><div>PO Box 97</div><div>Chatham NY 12037</div><div><b>Phone:</b> 518-392-2150</div><div><b>Email:</b> hello@m-cm.net</div><div><a href="https://www.m-cm.net/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.m-cm.net</a></div></li><li class="half_rhythm"><div><b>M-CM Network Contact Registry</b></div><div><i>The M-CM Network contact registry will be used to inform individuals with M-CM and their guardians about: opportunities to participate in research, opportunities to contribute data, and discoveries about M-CM that may impact care decisions.</i></div><div><a href="https://www.m-cm.net/contact-registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Contact Registry</a></div></li></ul></div><div id="pik3ca-overgrowth.Molecular_Genetics"><h2 id="_pik3ca-overgrowth_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="pik3ca-overgrowth.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>PIK3CA-Related Segmental Overgrowth: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5290" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PIK3CA</i></a></td><td headers="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5290" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3q26<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P42336" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform</a></td><td headers="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/PIK3CA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PIK3CA database</a></td><td headers="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PIK3CA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PIK3CA</a></td><td headers="hd_b_pik3ca-overgrowth.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PIK3CA[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PIK3CA</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="pik3ca-overgrowth.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="pik3ca-overgrowth.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for PIK3CA-Related Segmental Overgrowth (<a href="/omim/171834,602501,612918" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/171834" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">171834</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, ALPHA; PIK3CA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602501" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602501</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612918" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612918</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI</td></tr></tbody></table></div></div><div id="pik3ca-overgrowth.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The PI3Ks are members of a unique and highly conserved family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides, a reaction that leads to the activation of many complex and intricate intracellular signaling pathways including the PI3K-AKT-mTOR network. Class IA PI3Ks are activated by growth factor receptor tyrosine kinases (RTKs) and are composed of heterodimers of p110 catalytic and p85 regulatory subunits, each of which has several <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> encoded by three genes; <i>PIK3R1, PIK3R2,</i> and <i>PIK3R3</i> encode the p85&#x003b1;, p55&#x003b1;, p50&#x003b1;, p85&#x003b2;, and p55&#x003b3; isoforms of the p85 regulatory subunit, while <i>PIK3CA</i>, <i>PIK3CB,</i> and <i>PIK3CD</i> encode the highly homologous p110 catalytic subunit isoforms p110&#x003b1;, p110&#x003b2;, and p110&#x003b4;, respectively [<a class="bk_pop" href="#pik3ca-overgrowth.REF.fruman.1998.481">Fruman et al 1998</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.cantley.2002.1655">Cantley 2002</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.engelman.2006.606">Engelman et al 2006</a>].</p><p>Somatic pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants <i>PIK3CA</i> are frequently found in individuals without <i>PIK3CA</i>-related overgrowth in diverse cancers including colon, breast, brain, liver, stomach, and lung. See <a href="#pik3ca-overgrowth.Cancer_and_Benign_Tumo">Cancer and Benign Tumors</a>.</p><p><b>Gene structure.</b> The <i>PIK3CA</i> (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>) encodes the p110&#x003b1; catalytic subunit of class IA PI3K. <i>PIK3CA</i> (<a href="/nuccore/NM_006218.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_006218.2</a>) comprises 21 coding exons. For a detailed summary of gene and protein information, see <a href="/books/NBK153722/#pik3ca-overgrowth.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> A number of benign variants have been identified [<a class="bk_pop" href="#pik3ca-overgrowth.REF.quaye.2009.993">Quaye et al 2009</a>]. A <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a> with greater than 95% homology spanning exons 9 to 13 of <i>PIK3CA</i> on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 22 exists [<a class="bk_pop" href="#pik3ca-overgrowth.REF.m_ller.2007.27">M&#x000fc;ller et al 2007</a>].</p><p><b>Pathogenic variants.</b> Eighteen pathogenic variants have been reported in MCAP syndrome, hemimegalencephaly (HMEG), and CLOVES syndrome and fibroadipose hyperplasia [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lee.2012.941">Lee et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>]. See <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.molecular_genetic_te/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTmoleculargeneticte" rid-ob="figobpik3caovergrowthTmoleculargeneticte">Table 3</a> and <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">Table 4</a>.</p><ul><li class="half_rhythm"><div><b>MCAP syndrome.</b> The <i>PIK3CA</i> variant spectrum in MCAP syndrome is wide. <i>PIK3CA</i> pathogenic variants were detected in 24 individuals with MCAP syndrome using both standard and massively parallel sequencing methods [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>]. It is currently unknown whether MCAP syndrome is genetically heterogeneous or the individuals with MCAP syndrome of unknown cause are in fact <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for low-level mosaic <i>PIK3CA</i> pathogenic variants undetected in the tissue(s) tested.</div></li><li class="half_rhythm"><div><b>CLOVES syndrome and fibroadipose hyperplasia.</b> Mosaic <i>PIK3CA</i> pathogenic variants from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (or lesional) tissues were identified in six individuals with CLOVES syndrome and ten individuals with fibroadipose hyperplasia [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>]. See <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">Table 4</a>.</div></li></ul><div id="pik3ca-overgrowth.T.select_pik3ca_varian" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Select <i>PIK3CA</i> Variants Causing <i>PIK3CA</i>-Related Overgrowth Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.T.select_pik3ca_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Overgrowth Phenotype (N)</th><th id="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1258T&#x0003e;C</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys420Arg</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CLOVES (2)</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_4" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_006218.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_006218<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_006209.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_006209<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1625G&#x0003e;A</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu542Lys</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CLOVES (2)</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1633G&#x0003e;A</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu545Lys</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HMEG (4)&#x000a0;<sup>1</sup>, MCAP-plus (1)&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3140A&#x0003e;G</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His1047Arg</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CLOVES-FH (9), KTS (3)</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3140A&#x0003e;T</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His1047Leu</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CLOVES-FH (2)</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Others</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Others</td><td headers="hd_h_pik3ca-overgrowth.T.select_pik3ca_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MCAP (23)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="pik3ca-overgrowth.TF.4.1"><p class="no_margin">p.Glu545Lys was identified in all four <i>PIK3CA</i>-positive brain tissue samples from individuals with HMEG [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lee.2012.941">Lee et al 2012</a>].</p></div></dd><dt>2. </dt><dd><div id="pik3ca-overgrowth.TF.4.2"><p class="no_margin">See <a href="#pik3ca-overgrowth.Cancer_and_Benign_Tumo">Cancer and Benign Tumors</a> for a description of this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div></dd></dl></div></div></div><p>Many of the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>PIK3CA</i> have been found in human cancers. See <a href="#pik3ca-overgrowth.Cancer_and_Benign_Tumo">Cancer and Benign Tumors</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>PIK3CA</i> encodes 1068 amino acids of the p110&#x003b1; catalytic subunit of class IA PI3K. Similar to most genes encoding PI3Ks, <i>PIK3CA</i> is widely expressed. p110&#x003b1; is characterized by five functional domains: p85-regulatory subunit-binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (p85-BD), Ras-binding domain (Ras-BD), C2 domain, helical domain, and kinase catalytic domain [<a class="bk_pop" href="#pik3ca-overgrowth.REF.chalhoub.2009.127">Chalhoub &#x00026; Baker 2009</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> In cell lines from individuals with <i>PIK3CA</i>-associated overgrowth, stimulation of cells resulted in increased basal hyperphosphorylation of AKT and its downstream targets (e.g., p70S6 kinases), suggesting that <i>PIK3CA</i> pathogenic variants in <i>PIK3CA</i>-associated overgrowth result in enhanced basal activity and activation of downstream signaling of the PI3K-AKT pathway [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>].</p></div><div id="pik3ca-overgrowth.Cancer_and_Benign_Tumo"><h3>Cancer and Benign Tumors</h3><p>Somatic pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <i>PIK3CA</i> are frequently found in diverse cancer types including ovary, breast, lung, brain, stomach, and up to 15%-20% of colorectal cancers. The helical and kinase domains are particular hot spots for somatic pathogenic variants in cancer [<a class="bk_pop" href="#pik3ca-overgrowth.REF.janku.2011.e22769">Janku et al 2011</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.janku.2012.1566">Janku et al 2012</a>]. All cancer-associated <i>PIK3CA</i> variants for which functional data are available were shown to result in increased PI3K activity and/or signaling [<a class="bk_pop" href="#pik3ca-overgrowth.REF.shayesteh.1999.99">Shayesteh et al 1999</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.liu.2011.1116">Liu et al 2011</a>]. Detectable amplification of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> has also been shown in 58% of ovarian tumors using fluorescence in situ hybridization [<a class="bk_pop" href="#pik3ca-overgrowth.REF.shayesteh.1999.99">Shayesteh et al 1999</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.zhang.2003.4225">Zhang et al 2003</a>].</p><p>Among the approximately 160 <i>PIK3CA</i> pathogenic variants listed in the Catalogue of Somatic Mutations in Cancer (COSMIC), common variants in four amino acids (p.Glu542Lys, p.Glu545Lys in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9, and p.His1047Arg and p.His1047Leu in exon 20) account for 80% of tumor-associated <i>PIK3CA</i> variants and show the highest oncogenic activity [<a class="bk_pop" href="#pik3ca-overgrowth.REF.samuels.2004.554">Samuels et al 2004</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.samuels.2006.77">Samuels &#x00026; Ericson 2006</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.janku.2012.1566">Janku et al 2012</a>]. See <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.common_cancerrelated/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTcommoncancerrelated" rid-ob="figobpik3caovergrowthTcommoncancerrelated">Table 5</a>.</p><div id="pik3ca-overgrowth.T.common_cancerrelated" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Common Cancer-Related <i>PIK3CA</i> Variants Reported in COSMIC Database</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK153722/table/pik3ca-overgrowth.T.common_cancerrelated/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pik3ca-overgrowth.T.common_cancerrelated_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"># of Cancer Specimens with the Pathogenic Variant</th></tr></thead><tbody><tr><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1625G&#x0003e;A</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu542Lys</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">633</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1633G&#x0003e;A</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu545Lys</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">977</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3140A&#x0003e;G</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His1047Arg</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1680</td></tr><tr><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3140A&#x0003e;T</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His1047Leu</td><td headers="hd_h_pik3ca-overgrowth.T.common_cancerrelated_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">201</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a href="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COSMIC: Catalogue of Somatic Mutations in Cancer</a></p></div></dd></dl></div></div></div><p>The same four <i>PIK3CA</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants may be found in individuals with <i>PIK3CA</i>-associated overgrowth and in unaffected individuals with <i>PIK3CA</i>-related cancer (<a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">Table 4</a> and <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.common_cancerrelated/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTcommoncancerrelated" rid-ob="figobpik3caovergrowthTcommoncancerrelated">Table 5</a>). Preliminary analysis (see <a href="#pik3ca-overgrowth.GenotypePhenotype_Corr">Genotype-Phenotype Correlations</a>) of individuals with <i>PIK3CA</i>-associated segmental overgrowth suggests that MCAP syndrome is primarily associated with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for <i>PIK3CA</i> pathogenic variants not commonly identified in tumors, whereas hemimegalencephaly and CLOVES syndrome are associated with somatic mosaicism for <i>PIK3CA</i> pathogenic variants at the cancer-related mutational hot spots (see <a href="#pik3ca-overgrowth.Molecular_Pathogenesis">Molecular Pathogenesis</a>, <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">Table 4</a>, and <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.common_cancerrelated/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTcommoncancerrelated" rid-ob="figobpik3caovergrowthTcommoncancerrelated">Table 5</a>).</p><ul><li class="half_rhythm"><div><b>HMEG.</b> p.Glu545Lys was identified in brain tissues of all four individuals with HMEG [<a class="bk_pop" href="#pik3ca-overgrowth.REF.lee.2012.941">Lee et al 2012</a>].</div></li><li class="half_rhythm"><div><b>MCAP syndrome.</b> While 13 of the 15 reported <i>PIK3CA</i> pathogenic variants in MCAP syndrome are reported in <a href="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COSMIC</a>, only one (p.Glu545Lys) was at a site commonly mutated in <i>PIK3CA</i>-related cancers. This was identified in a child with atypical MCAP syndrome features that overlapped with CLOVES syndrome and hemimegalencephaly, including severe asymmetric brain overgrowth, bilateral cortical dysplasia, severe focal overgrowth of the digits, and epidermal nevi (designated as MCAP-plus in <a class="figpopup" href="/books/NBK153722/table/pik3ca-overgrowth.T.select_pik3ca_varian/?report=objectonly" target="object" rid-figpopup="figpik3caovergrowthTselectpik3cavarian" rid-ob="figobpik3caovergrowthTselectpik3cavarian">Table 4</a>) [<a class="bk_pop" href="#pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re et al 2012</a>].</div></li><li class="half_rhythm"><div><b>CLOVES syndrome and fibroadipose hyperplasia.</b> 14 individuals with these phenotypes have <i>PIK3CA</i> pathogenic variants involving three of the four cancer mutational hot spots [<a class="bk_pop" href="#pik3ca-overgrowth.REF.kurek.2012.1108">Kurek et al 2012</a>, <a class="bk_pop" href="#pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst et al 2012</a>].</div></li></ul></div></div><div id="pik3ca-overgrowth.References"><h2 id="_pik3ca-overgrowth_References_">References</h2><div id="pik3ca-overgrowth.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.abdelhalim.2003.534">Abdelhalim AN, Moritani T, Richfield E, Ekholm SE, Westesson PL. Epidermal nevus syndrome: megalencephaly with bihemispheric and cerebellar involvement: imaging and neuropathologic correlation. <span><span class="ref-journal">J Comput Assist Tomogr. </span>2003;<span class="ref-vol">27</span>:534–7.</span> [<a href="/pubmed/12886138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12886138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.akcar.2004.261">Akcar N, Adapinar B, Dinleyici C, Durak B, Ozkan IR. A case of macrocephaly-cutis marmorata telangiectatica congenita and review of neuroradiologic features. <span><span class="ref-journal">Ann Genet. </span>2004;<span class="ref-vol">47</span>:261–5.</span> [<a href="/pubmed/15337471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15337471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.alomari.2010.459">Alomari AI, Burrows PE, Lee EY, Hedequist DJ, Mulliken JB, Fishman SJ. CLOVES syndrome with thoracic and central phlebectasia: increased risk of pulmonary embolism. <span><span class="ref-journal">J Thorac Cardiovasc Surg. </span>2010;<span class="ref-vol">140</span>:459–63.</span> [<a href="/pubmed/20537357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20537357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.alomari.2011.1812">Alomari AI, Chaudry G, Rodesch G, Burrows PE, Mulliken JB, Smith ER, Fishman SJ, Orbach DB. Complex spinal-paraspinal fast-flow lesions in CLOVES syndrome: analysis of clinical and imaging findings in 6 patients. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2011;<span class="ref-vol">32</span>:1812–7.</span> [<a href="/pubmed/21310861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21310861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.alomari.2009a.1">Alomari AI. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. <span><span class="ref-journal">Clin Dysmorphol. </span>2009a;<span class="ref-vol">18</span>:1–7.</span> [<a href="/pubmed/19011570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19011570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.alomari.2009b.294">Alomari AI. CLOVE(S) syndrome: expanding the acronym. <span><span class="ref-journal">Am J Med Genet A. </span>2009b;<span class="ref-vol">149A</span>:294.</span> [<a href="/pubmed/19161149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19161149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.alomari.2011.215">Alomari AI. Comments on the diagnosis and management of CLOVES syndrome. <span><span class="ref-journal">Pediatr Dermatol. </span>2011;<span class="ref-vol">28</span>:215–6.</span> [<a href="/pubmed/21504461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21504461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.barkovich.1990.523">Barkovich AJ, Chuang SH. Unilateral megalencephaly: correlation of MR imaging and pathologic characteristics. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>1990;<span class="ref-vol">11</span>:523–31.</span> [<a href="/pubmed/1693466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1693466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.barkovich.2005.1873">Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. A developmental and genetic classification for malformations of cortical development. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:1873–87.</span> [<a href="/pubmed/16192428" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16192428</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.biesecker.1999.389">Biesecker LG, Happle R, Mulliken JB, Weksberg R, Graham JM Jr, Viljoen DL, Cohen MM Jr. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">84</span>:389–95.</span> [<a href="/pubmed/10360391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10360391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.cantley.2002.1655">Cantley LC. The phosphoinositide 3-kinase pathway. <span><span class="ref-journal">Science. </span>2002;<span class="ref-vol">296</span>:1655–7.</span> [<a href="/pubmed/12040186" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12040186</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.caux.2007.767">Caux F, Plauchu H, Chibon F, Faivre L, Fain O, Vabres P, Bonnet F, Selma ZB, Laroche L, G&#x000e9;rard M, Longy M. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. <span><span class="ref-journal">Eur J Hum Genet. </span>2007;<span class="ref-vol">15</span>:767–73.</span> [<a href="/pubmed/17392703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17392703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.chalhoub.2009.127">Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. <span><span class="ref-journal">Annu Rev Pathol. </span>2009;<span class="ref-vol">4</span>:127–50.</span> [<a href="/pmc/articles/PMC2710138/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2710138</span></a>] [<a href="/pubmed/18767981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18767981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.claytonsmith.1997.291">Clayton-Smith J, Kerr B, Brunner H, Tranebjaerg L, Magee A, Hennekam RC, Mueller RF, Brueton L, Super M, Steen-Johnsen J, Donnai D. Macrocephaly with cutis marmorata, haemangioma and syndactyly--a distinctive overgrowth syndrome. <span><span class="ref-journal">Clin Dysmorphol. </span>1997;<span class="ref-vol">6</span>:291–302.</span> [<a href="/pubmed/9354837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9354837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.cohen.2003.49">Cohen MM Jr. Mental deficiency, alterations in performance, and CNS abnormalities in overgrowth syndromes. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2003;<span class="ref-vol">117C</span>:49–56.</span> [<a href="/pubmed/12561058" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12561058</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.colombani.2006.466">Colombani M, Chouchane M, Pitelet G, Morales L, Callier P, Pinard JP, Lion-Fran&#x000e7;ois L, Thauvin-Robinet C, Mugneret F, Huet F, Guibaud L, Faivre L. A new case of megalencephaly and perisylvian polymicrogyria with post-axial polydactyly and hydrocephalus: MPPH syndrome. <span><span class="ref-journal">Eur J Med Genet. </span>2006;<span class="ref-vol">49</span>:466–71.</span> [<a href="/pubmed/16807158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16807158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.conway.2007a.296">Conway RL, Danielpour M, Graham JM Jr. Surgical management of cerebellar tonsillar herniation in three patients with macrocephaly-cutis marmorata telangiectatica congenita. Report of three cases. <span><span class="ref-journal">J Neurosurg. </span>2007a;<span class="ref-vol">106</span>:296–301.</span> [<a href="/pubmed/17465364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17465364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.conway.2007b.2981">Conway RL, Pressman BD, Dobyns WB, Danielpour M, Lee J, Sanchez-Lara PA, Butler MG, Zackai E, Campbell L, Saitta SC, Clericuzio CL, Milunsky JM, Hoyme HE, Shieh J, Moeschler JB, Crandall B, Lauzon JL, Viskochil DH, Harding B, Graham JM Jr. Neuroimaging findings in macrocephaly-capillary malformation: a longitudinal study of 17 patients. <span><span class="ref-journal">Am J Med Genet A. </span>2007b;<span class="ref-vol">143A</span>:2981–3008.</span> [<a href="/pmc/articles/PMC6816457/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6816457</span></a>] [<a href="/pubmed/18000912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18000912</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.coste.2012.917">Coste K, Sarret C, Cisse A, Delabaere A, Francannet C, Vanlieferinghen P. Macrocephaly-capillary malformation. A neonatal case. <span><span class="ref-journal">Arch Pediatr. </span>2012;<span class="ref-vol">19</span>:917–20.</span> [<a href="/pubmed/22884750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22884750</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.debaun.1998.398">DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. <span><span class="ref-journal">J Pediatr. </span>1998;<span class="ref-vol">132</span>:398–400.</span> [<a href="/pubmed/9544889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9544889</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.di_rocco.2006.852">Di Rocco C, Battaglia D, Pietrini D, Piastra M, Massimi L. Hemimegalencephaly: clinical implications and surgical treatment. <span><span class="ref-journal">Childs Nerv Syst. </span>2006;<span class="ref-vol">22</span>:852–66.</span> [<a href="/pubmed/16821075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16821075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.dinleyici.2004.366">Dinleyici EC, Tekin N, Aksit MA, Kilic Z, Adapinar B, Bozan G. Macrocephaly-Cutis marmorata telangiectatica congenita with atrial septal aneurysm and magnetic resonance imaging (MRI) findings. <span><span class="ref-journal">Pediatr Int. </span>2004;<span class="ref-vol">46</span>:366–7.</span> [<a href="/pubmed/15151560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15151560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.engelman.2006.606">Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. <span><span class="ref-journal">Nat Rev Genet. </span>2006;<span class="ref-vol">7</span>:606–19.</span> [<a href="/pubmed/16847462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16847462</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.ercan.2013.115">Ercan TE, Oztunc F, Celkan T, Bor M, Kizilkilic O, Vural M, Perk Y, Islak C, Tuysuz B. Macrocephaly-capillary malformation syndrome in a newborn with tetralogy of fallot and sagittal sinus thrombosis. <span><span class="ref-journal">J Child Neurol. </span>2013;<span class="ref-vol">28</span>:115–9.</span> [<a href="/pubmed/22451530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22451530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.floressarnat.2003.776">Flores-Sarnat L, Sarnat HB, D&#x000e1;vila-Guti&#x000e9;rrez G, Alvarez A. Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. <span><span class="ref-journal">J Child Neurol. </span>2003;<span class="ref-vol">18</span>:776–85.</span> [<a href="/pubmed/14696906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14696906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.floressarnat.2002.373">Flores-Sarnat L. Hemimegalencephaly: part 1. Genetic, clinical, and imaging aspects. <span><span class="ref-journal">J Child Neurol. </span>2002;<span class="ref-vol">17</span>:373–84.</span> [<a href="/pubmed/12150586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12150586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.franceschini.2000.265">Franceschini P, Licata D, Di Cara G, Guala A, Franceschini D, Genitori L. Macrocephaly-Cutis marmorata telangiectatica congenita without cutis marmorata? <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">90</span>:265–9.</span> [<a href="/pubmed/10710221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10710221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.fruman.1998.481">Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. <span><span class="ref-journal">Annu Rev Biochem. </span>1998;<span class="ref-vol">67</span>:481–507.</span> [<a href="/pubmed/9759495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9759495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.garavelli.2007.200">Garavelli L, Guareschi E, Errico S, Simoni A, Bergonzini P, Zollino M, Gurrieri F, Mancini GM, Schot R, Van Der Spek PJ, Frigieri G, Zonari P, Albertini E, Giustina ED, Amarri S, Banchini G, Dobyns WB, Neri G. Megalencephaly and perisylvian polymicrogyria with postaxial polydactyly and hydrocephalus (MPPH): report of a new case. <span><span class="ref-journal">Neuropediatrics. </span>2007;<span class="ref-vol">38</span>:200–3.</span> [<a href="/pubmed/18058629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18058629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.giuliano.2004.99">Giuliano F, David A, Edery P, Sigaudy S, Bonneau D, Cormier-Daire V, Philip N. Macrocephaly-cutis marmorata telangiectatica congenita: seven cases including two with unusual cerebral manifestations. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">126A</span>:99–103.</span> [<a href="/pubmed/15039980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15039980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.gripp.2009.868">Gripp KW, Hopkins E, Vinkler C, Lev D, Malinger G, Lerman-Sagie T, Dobyns WB. Significant overlap and possible identity of macrocephaly capillary malformation and megalencephaly polymicrogyria-polydactyly hydrocephalus syndromes. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:868–76.</span> [<a href="/pubmed/19353582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19353582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.gucev.2008.2688">Gucev ZS, Tasic V, Jancevska A, Konstantinova MK, Pop-Jordanova N, Trajkovski Z, Biesecker LG. Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE) syndrome: CNS malformations and seizures may be a component of this disorder. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:2688–90.</span> [<a href="/pmc/articles/PMC2819374/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2819374</span></a>] [<a href="/pubmed/18816642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18816642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.janku.2011.e22769">Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e22769.</span> [<a href="/pmc/articles/PMC3146490/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3146490</span></a>] [<a href="/pubmed/21829508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21829508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.janku.2012.1566">Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. <span><span class="ref-journal">Oncotarget. </span>2012;<span class="ref-vol">3</span>:1566–75.</span> [<a href="/pmc/articles/PMC3681495/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3681495</span></a>] [<a href="/pubmed/23248156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23248156</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.kariminejad.2013.651">Kariminejad A, Radmanesh F, Rezayi AR, Tonekaboni SH, Gleeson JG. Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome: a case report. <span><span class="ref-journal">J Child Neurol. </span>2013;<span class="ref-vol">28</span>:651–7.</span> [<a href="/pubmed/22859694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22859694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.klein.2012.1690">Klein S, Stroberg A, Ghahremani S, Martinez-Agosto JA. Phenotypic progression of skeletal anomalies in CLOVES syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:1690–5.</span> [<a href="/pubmed/22628280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22628280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.kuint.2012.384">Kuint J, Globus O, Ben Simon GJ, Greenberger S. Macrocephaly-capillary malformation presenting with fetal arrhythmia. <span><span class="ref-journal">Pediatr Dermatol. </span>2012;<span class="ref-vol">29</span>:384–6.</span> [<a href="/pubmed/22329570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22329570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.kurek.2012.1108">Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP, Warman ML. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2012;<span class="ref-vol">90</span>:1108–15.</span> [<a href="/pmc/articles/PMC3370283/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3370283</span></a>] [<a href="/pubmed/22658544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22658544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.kwan.2008.643">Kwan SY, Shyu HY, Lin JH, Wong TT, Chang KP, Yiu CH. Corpus callosotomy in a patient of hemimegalencephaly and Lennox-Gastaut syndrome. <span><span class="ref-journal">Brain Dev. </span>2008;<span class="ref-vol">30</span>:643–6.</span> [<a href="/pubmed/18439776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18439776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.lapunzina.2004.45">Lapunzina P, Gair&#x000ed; A, Delicado A, Mori MA, Torres ML, Goma A, Navia M, Pajares IL. Macrocephaly-cutis marmorata telangiectatica congenita: report of six new patients and a review. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">130A</span>:45–51.</span> [<a href="/pubmed/15368495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15368495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.lee.2012.941">Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:941–5.</span> [<a href="/pmc/articles/PMC4417942/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4417942</span></a>] [<a href="/pubmed/22729223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22729223</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.lindhurst.2012.928">Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJ, Barroso I, Biesecker LG, Semple RK. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:928–33.</span> [<a href="/pmc/articles/PMC3461408/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3461408</span></a>] [<a href="/pubmed/22729222" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22729222</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.lindhurst.2011.611">Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">365</span>:611–9.</span> [<a href="/pmc/articles/PMC3170413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3170413</span></a>] [<a href="/pubmed/21793738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21793738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.liu.2011.1116">Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. <span><span class="ref-journal">Nat Med. </span>2011;<span class="ref-vol">17</span>:1116–20.</span> [<a href="/pmc/articles/PMC3169724/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3169724</span></a>] [<a href="/pubmed/21822287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21822287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.mart_nezglez.2010.3101">Mart&#x000ed;nez-Glez V, Romanelli V, Mori MA, Gracia R, Segovia M, Gonz&#x000e1;lez-Meneses A, L&#x000f3;pez-Gutierrez JC, Gean E, Martorell L, Lapunzina P. Macrocephaly-capillary malformation: Analysis of 13 patients and review of the diagnostic criteria. <span><span class="ref-journal">Am J Med Genet A. </span>2010;<span class="ref-vol">152A</span>:3101–6.</span> [<a href="/pubmed/21077203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21077203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.mart_nezlage.2010.13">Mart&#x000ed;nez-Lage JF, Guill&#x000e9;n-Navarro E, Almagro MJ, Felipe-Murcia M, L&#x000f3;pez L&#x000f3;pez-Guerrero A, Galarza M. Hydrocephalus and Chiari type 1 malformation in macrocephaly-cutis marmorata telangiectatica congenita: a case-based update. <span><span class="ref-journal">Childs Nerv Syst. </span>2010;<span class="ref-vol">26</span>:13–8.</span> [<a href="/pubmed/19763591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19763591</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.mcbride.2010.137">McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF, Herman GE. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. <span><span class="ref-journal">Autism Res. </span>2010;<span class="ref-vol">3</span>:137–41.</span> [<a href="/pubmed/20533527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20533527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.m_garban_.2003.184">M&#x000e9;garban&#x000e9; A, Haddad J, Lyonnet S, Clayton-Smith J. Child with overgrowth, pigmentary streaks, polydactyly, and intestinal lymphangiectasia: macrocephaly-cutis marmorata telangiectatica congenita syndrome or new disorder? <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">116A</span>:184–7.</span> [<a href="/pubmed/12494441" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12494441</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.mirzaa.2004.353">Mirzaa G, Dodge NN, Glass I, Day C, Gripp K, Nicholson L, Straub V, Voit T, Dobyns WB. Megalencephaly and perisylvian polymicrogyria with postaxial polydactyly and hydrocephalus: a rare brain malformation syndrome associated with mental retardation and seizures. <span><span class="ref-journal">Neuropediatrics. </span>2004;<span class="ref-vol">35</span>:353–9.</span> [<a href="/pubmed/15627943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15627943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.mirzaa.2012.269">Mirzaa GM, Conway RL, Gripp KW, Lerman-Sagie T, Siegel DH, deVries LS, Lev D, Kramer N, Hopkins E, Graham JM Jr, Dobyns WB. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:269–91.</span> [<a href="/pubmed/22228622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22228622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.moore.1997.67">Moore CA, Toriello HV, Abuelo DN, Bull MJ, Curry CJ, Hall BD, Higgins JV, Stevens CA, Twersky S, Weksberg R, Dobyns WB. Macrocephaly-cutis marmorata telangiectatica congenita: a distinct disorder with developmental delay and connective tissue abnormalities. <span><span class="ref-journal">Am J Med Genet. </span>1997;<span class="ref-vol">70</span>:67–73.</span> [<a href="/pubmed/9129744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9129744</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.m_ller.2007.27">M&#x000fc;ller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, Luong QT, Koeffler HP. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. <span><span class="ref-journal">Leuk Res. </span>2007;<span class="ref-vol">31</span>:27–32.</span> [<a href="/pubmed/16764926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16764926</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.nyberg.2005.129">Nyberg RH, Uotila J, Kirkinen P, Rosendahl H. Macrocephaly-cutis marmorata telangiectatica congenita syndrome--prenatal signs in ultrasonography. <span><span class="ref-journal">Prenat Diagn. </span>2005;<span class="ref-vol">25</span>:129–32.</span> [<a href="/pubmed/15712320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15712320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.oduber.2011.262">Oduber CE, van der Horst CM, Sillevis Smitt JH, Smeulders MJ, Mendiratta V, Harper JI, van Steensel MA, Hennekam RC. A proposal for classification of entities combining vascular malformations and deregulated growth. <span><span class="ref-journal">Eur J Med Genet. </span>2011;<span class="ref-vol">54</span>:262–71.</span> [<a href="/pubmed/21356335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21356335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.orloff.2013.76">Orloff MS, He X, Peterson C, Chen F, Chen JL, Mester JL, Eng C. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:76–80.</span> [<a href="/pmc/articles/PMC3542473/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3542473</span></a>] [<a href="/pubmed/23246288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23246288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.osterling.2011.370">Osterling WL, Boyer RS, Hedlund GL, Bale JF Jr. MPPH syndrome: two new cases. <span><span class="ref-journal">Pediatr Neurol. </span>2011;<span class="ref-vol">44</span>:370–3.</span> [<a href="/pubmed/21481746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21481746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.pavlidis.2012.332">Pavlidis E, Cantalupo G, Boria S, Cossu G, Pisani F. Hemimegalencephalic variant of epidermal nevus syndrome: case report and literature review. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2012;<span class="ref-vol">16</span>:332–42.</span> [<a href="/pubmed/22200538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22200538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.pisano.2008.916">Pisano T, Meloni M, Cianchetti C, Falchi M, Nucaro A, Pruna D. Megalencephaly, polymicrogyria, and hydrocephalus (MPPH) syndrome: a new case with syndactyly. <span><span class="ref-journal">J Child Neurol. </span>2008;<span class="ref-vol">23</span>:916–8.</span> [<a href="/pubmed/18474936" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18474936</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.poduri.2012.41">Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. Somatic activation of AKT3 causes hemispheric developmental brain malformations. <span><span class="ref-journal">Neuron. </span>2012;<span class="ref-vol">74</span>:41–8.</span> [<a href="/pmc/articles/PMC3460551/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3460551</span></a>] [<a href="/pubmed/22500628" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22500628</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.quaye.2009.993">Quaye L, Song H, Ramus SJ, Gentry-Maharaj A, H&#x000f8;gdall E, DiCioccio RA, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Wozniak E, Doherty JA, Rossing MA, Ness RB, Moysich KB, H&#x000f8;gdall C, Blaakaer J., Ovarian Cancer Association Consortium.  Easton DF, Ponder BA, Jacobs IJ, Menon U, Whittemore AS, Kr&#x000fc;ger-Kjaer S, Pearce CL, Pharoah PD, Gayther SA. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. <span><span class="ref-journal">Br J Cancer. </span>2009;<span class="ref-vol">100</span>:993–1001.</span> [<a href="/pmc/articles/PMC2661781/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2661781</span></a>] [<a href="/pubmed/19240718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19240718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.rios.2013.444">Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, Ezaki M. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. <span><span class="ref-journal">Hum Mol Genet. </span>2013;<span class="ref-vol">22</span>:444–51.</span> [<a href="/pmc/articles/PMC3542862/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3542862</span></a>] [<a href="/pubmed/23100325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23100325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.rivi_re.2012.934">Rivi&#x000e8;re JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL., Finding of Rare Disease Genes (FORGE) Canada Consortium.  Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:934–40.</span> [<a href="/pmc/articles/PMC3408813/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3408813</span></a>] [<a href="/pubmed/22729224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22729224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.robertson.2000.1">Robertson SP, Gattas M, Rogers M, Ad&#x000e8;s LC. Macrocephaly--cutis marmorata telangiectatica congenita: report of five patients and a review of the literature. <span><span class="ref-journal">Clin Dysmorphol. </span>2000;<span class="ref-vol">9</span>:1–9.</span> [<a href="/pubmed/10649789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10649789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.samuels.2006.77">Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. <span><span class="ref-journal">Curr Opin Oncol. </span>2006;<span class="ref-vol">18</span>:77–82.</span> [<a href="/pubmed/16357568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16357568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.samuels.2004.554">Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. <span><span class="ref-journal">Science. </span>2004;<span class="ref-vol">304</span>:554.</span> [<a href="/pubmed/15016963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15016963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.sapp.2007.2944">Sapp JC, Turner JT, van de Kamp JM, van Dijk FS, Lowry RB, Biesecker LG. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. <span><span class="ref-journal">Am J Med Genet A. </span>2007;<span class="ref-vol">143A</span>:2944–58.</span> [<a href="/pubmed/17963221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17963221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.sharma.2009.12">Sharma S, Sankhyan N, Kabra M, Kumar A. Hypomelanosis of Ito with hemimegalencephaly. <span><span class="ref-journal">Dermatol Online J. </span>2009;<span class="ref-vol">15</span>:12.</span> [<a href="/pubmed/19951648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19951648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.shayesteh.1999.99">Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. <span><span class="ref-journal">Nat Genet. </span>1999;<span class="ref-vol">21</span>:99–102.</span> [<a href="/pubmed/9916799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9916799</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.thong.1999.283">Thong MK, Thompson E, Keenan R, Simmer K, Harbord M, Davidson G, Haan E. A child with hemimegalencephaly, hemihypertrophy, macrocephaly, cutaneous vascular malformation, psychomotor retardation and intestinal lymphangiectasia--a diagnostic dilemma. <span><span class="ref-journal">Clin Dysmorphol. </span>1999;<span class="ref-vol">8</span>:283–6.</span> [<a href="/pubmed/10532178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10532178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.tohyama.2007.148">Tohyama J, Akasaka N, Saito N, Yoshimura J, Nishiyama K, Kato M. Megalencephaly and polymicrogyria with polydactyly syndrome. <span><span class="ref-journal">Pediatr Neurol. </span>2007;<span class="ref-vol">37</span>:148–51.</span> [<a href="/pubmed/17675034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17675034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.tore.2009.1620">Tore HG, McKinney AM, Nagar VA, Lohman B, Truwit CL, Raybaud C. Syndrome of megalencephaly, polydactyly, and polymicrogyria lacking frank hydrocephalus, with associated MR imaging findings. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2009;<span class="ref-vol">30</span>:1620–2.</span> [<a href="/pubmed/19369601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19369601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.toriello.2007.3009">Toriello HV, Mulliken JB. Accurately renaming macrocephaly-cutis marmorata telangiectatica congenita (M-CMTC) as macrocephaly-capillary malformation (M-CM). <span><span class="ref-journal">Am J Med Genet A. </span>2007;<span class="ref-vol">143A</span>:3009.</span> [<a href="/pubmed/17963258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17963258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.verkerk.2010.1488">Verkerk AJ, Schot R, van Waterschoot L, Douben H, Poddighe PJ, Lequin MH, de Vries LS, Terhal P, Hahnemann JM, de Coo IF, de Wit MC, Wafelman LS, Garavelli L, Dobyns WB, Van der Spek PJ, de Klein A, Mancini GM. Unbalanced der(5)t(5;20) translocation associated with megalencephaly, perisylvian polymicrogyria, polydactyly and hydrocephalus. <span><span class="ref-journal">Am J Med Genet A. </span>2010;<span class="ref-vol">152A</span>:1488–97.</span> [<a href="/pmc/articles/PMC2908594/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2908594</span></a>] [<a href="/pubmed/20503325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20503325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.vogels.1998.245">Vogels A, Devriendt K, Legius E, Decock P, Marien J, Hendrickx G, Fryns JP. The macrocephaly-cutis marmorata telangiectatica congenita syndrome. Long-term follow-up data in 4 children and adolescents. <span><span class="ref-journal">Genet Couns. </span>1998;<span class="ref-vol">9</span>:245–53.</span> [<a href="/pubmed/9894160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9894160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.wright.2009.287">Wright DR, Frieden IJ, Orlow SJ, Shin HT, Chamlin S, Schaffer JV, Paller AS. The misnomer "macrocephaly-cutis marmorata telangiectatica congenita syndrome": report of 12 new cases and support for revising the name to macrocephaly-capillary malformations. <span><span class="ref-journal">Arch Dermatol. </span>2009;<span class="ref-vol">145</span>:287–93.</span> [<a href="/pubmed/19289759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19289759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.yano.2001.149">Yano S, Watanabe Y. Association of arrhythmia and sudden death in macrocephaly-cutis marmorata telangiectatica congenita syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">102</span>:149–52.</span> [<a href="/pubmed/11477607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11477607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pik3ca-overgrowth.REF.zhang.2003.4225">Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W, Rubin SC, Coukos G. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. <span><span class="ref-journal">Cancer Res. </span>2003;<span class="ref-vol">63</span>:4225–31.</span> [<a href="/pubmed/12874030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12874030</span></a>]</div></li></ul></div></div><div id="pik3ca-overgrowth.Chapter_Notes"><h2 id="_pik3ca-overgrowth_Chapter_Notes_">Chapter Notes</h2><div id="pik3ca-overgrowth.Author_Notes"><h3>Author Notes</h3><p>Drs Ghayda Mirzaa and William B Dobyns study the developmental basis of a broad range of developmental brain disorders, with a particular focus on megalencephaly syndromes. They are studying the natural history of <i>PI3KCA</i>-associated megalencephaly syndromes and related phenotypes.</p></div><div id="pik3ca-overgrowth.Acknowledgments"><h3>Acknowledgments</h3><p>We would like to thank the patients, their families, and our collaborators for their valuable contribution to our knowledge about these disorders.</p></div><div id="pik3ca-overgrowth.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 August 2013 (me) Review posted live</div></li><li class="half_rhythm"><div>11 March 2013 (gm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK153722</span><span class="label">PMID: <a href="/pubmed/23946963" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">23946963</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aniridia/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/pink1-pd/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK153722&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK153722/?report=reader">PubReader</a></li><li><a href="/books/NBK153722/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK153722" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK153722" style="display:none" title="Cite this Page"><div class="bk_tt">Mirzaa G, Conway R, Graham JM Jr, et al. PIK3CA-Related Segmental Overgrowth. 2013 Aug 15. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK153722/pdf/Bookshelf_NBK153722.pdf">PDF version of this page</a> (848K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#pik3ca-overgrowth.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#pik3ca-overgrowth.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#pik3ca-overgrowth.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#pik3ca-overgrowth.Clinical_Characteristi" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#pik3ca-overgrowth.Genetically_Related_Al" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#pik3ca-overgrowth.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#pik3ca-overgrowth.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#pik3ca-overgrowth.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#pik3ca-overgrowth.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#pik3ca-overgrowth.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#pik3ca-overgrowth.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#pik3ca-overgrowth.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5290[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PIK3CA</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK153722+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3048884" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3048884" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3048884" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3048884" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27854409" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> MPPH Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> MPPH Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mirzaa G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25557259" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.</a><span class="source">[Am J Med Genet A. 2015]</span><div class="brieflinkpop offscreen_noflow">PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2015 Feb; 167A(2):287-95. Epub 2014 Dec 31.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24782230" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.</a><span class="source">[Am J Med Genet A. 2014]</span><div class="brieflinkpop offscreen_noflow">Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, Tosi LL, Huson SM, Whitehouse RW, Jakkula E, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2014 Jul; 164A(7):1713-33. Epub 2014 Apr 29.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23592320" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.</a><span class="source">[Am J Med Genet C Semin Med Gen...]</span><div class="brieflinkpop offscreen_noflow">Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mirzaa GM, Rivière JB, Dobyns WB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet C Semin Med Genet. 2013 May; 163C(2):122-30. Epub 2013 Apr 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28577738" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [PIK3CA-related overgrowth syndrome (PROS)].</a><span class="source">[Nephrol Ther. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [PIK3CA-related overgrowth syndrome (PROS)].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Venot Q, Canaud G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nephrol Ther. 2017 Apr; 13 Suppl 1:S155-S156. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=23946963" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=23946963" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04118add21425a25a4d751">PIK3CA-Related Segmental Overgrowth - GeneReviews®</a><div class="ralinkpop offscreen_noflow">PIK3CA-Related Segmental Overgrowth - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:48:58-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CCD59E04012810000000006C40262&amp;ncbi_session=CE8CCD59E04118A1_1732SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK153722%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK153722&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK153722/&amp;ncbi_pagename=PIK3CA-Related Segmental Overgrowth - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CCD59E04118A1_1732SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>